Poliovirus Vaccine, Inactivated
Poliovirus Vaccine, Oral
Poliovirus
Poliovirus Vaccines
Poliomyelitis
Oman
Vaccines, Inactivated
Immunization Schedule
Vaccines
Vaccination
Virus Shedding
Immunization Programs
Injections, Jet
Viral Vaccines
Diphtheria-Tetanus-Pertussis Vaccine
Diphtheria-Tetanus-acellular Pertussis Vaccines
Vaccines, Synthetic
Vaccines, DNA
Bacterial Vaccines
Immunization, Secondary
Drug Contamination
Haemophilus Vaccines
AIDS Vaccines
Cuba
Vaccines, Attenuated
Egypt
Paralysis
Hepatitis B Vaccines
Feces
Vaccines, Conjugate
Vaccines, Subunit
Neutralization Tests
Afghanistan
Injections, Intradermal
Malaria Vaccines
Disease Outbreaks
Injections, Intramuscular
Papillomavirus Vaccines
Meningococcal Vaccines
HeLa Cells
Molecular Sequence Data
Immunity, Mucosal
Measles Vaccine
Antibody Formation
Pertussis Vaccine
Virulence
BCG Vaccine
Base Sequence
Rabies Vaccines
Population Surveillance
Simian virus 40
World Health Organization
Cholera Vaccines
Seroepidemiologic Studies
Typhoid-Paratyphoid Vaccines
Virus Replication
Receptors, Virus
Enterovirus
Smallpox Vaccine
Chickenpox Vaccine
Poisson Distribution
Mumps Vaccine
United States
Hepatitis A Vaccines
Adjuvants, Immunologic
Immunization
Incidence
India
Dengue Vaccines
Enterovirus B, Human
Vaccines, Virosome
Cysteine Endopeptidases
Viral Hepatitis Vaccines
Yellow Fever Vaccine
Plague Vaccine
Fungal Vaccines
Polymerase Chain Reaction
Protein Biosynthesis
RNA Replicase
Mice, Inbred BALB C
Cluster survey evaluation of coverage and risk factors for failure to be immunized during the 1995 National Immunization Days in Egypt. (1/545)
BACKGROUND: In 1995, Egypt continued to experience endemic wild poliovirus transmission despite achieving high routine immunization coverage with at least three doses of oral poliovirus vaccine (OPV3) and implementing National Immunization Days (NIDs) annually for several years. METHODS: Parents of 4188 children in 3216 households throughout Egypt were surveyed after the second round of the 1995 NIDs. RESULTS: Nationwide, 74% of children are estimated to have received both NID doses, 17% one NID dose, and 9% neither NID dose. Previously unimmunized (47%) or partially immunized (64%) children were less likely to receive two NID doses of OPV than were fully immunized children (76%) (P < 0.001). Other risk factors nationwide for failure to receive NID OPV included distance from residence to nearest NID site >10 minute walk (P < 0.001), not being informed about the NID at least one day in advance (P < 0.001), and residing in a household which does not watch television (P < 0.001). Based on these findings, subsequent NIDs in Egypt were modified to improve coverage, which has resulted in a marked decrease in the incidence of paralytic poliomyelitis in Egypt. CONCLUSIONS: In selected situations, surveys can provide important information that is useful for planning future NIDs. (+info)Progress toward poliomyelitis eradication--Pakistan, 1994-1998. (2/545)
Since the 1988 World Health Assembly resolution to eradicate poliomyelitis by 2000, polio cases reported globally have decreased by approximately 85%. Despite a strong commitment to polio eradication, polio remains endemic in Pakistan. In 1997, Pakistan reported 1147 polio cases, representing widespread poliovirus circulation nationally and constituting 22% of cases reported worldwide. However, surveillance and laboratory data from 1998 indicate that previous widespread poliovirus circulation was geographically localized for the first time. This report describes polio eradication activities in Pakistan, including the impact of routine and supplementary vaccination on polio incidence. (+info)Wild poliovirus circulation among healthy children immunized with oral polio vaccine in Antananarivo, Madagascar. (3/545)
From July 1995 to December 1996, 3185 stool specimens from healthy children aged 6-59 months attending 6 dispensaries in the Antananarivo area were examined for poliovirus. The children had been routinely immunized according to the Expanded Programme on Immunization (EPI) schedule and received the last dose of oral polio vaccine (OPV) more than 1 month before stool collection. 99.4% of the children were immunized with at least 3 doses of OPV. HEp-2 cell culture revealed virus infections in 192 stools (6.0%), including 9 poliovirus (0.3%) and 183 nonpolio enterovirus isolates (5.7%). Infections occurred throughout the year, but incidence was higher during the hot and rainy season (P=0.01). Using a neutralization test with monoclonal antibodies and PCR-RFLP in two genomic regions coding for the VP1 capsid and RNA polymerase, 4 wild polioviruses (3 type 1 and 1 type 3) and 5 vaccine-related polioviruses (2 Sabin 1-like variants, 1 Sabin 2-like and 2 Sabin 3-like) strains were identified. The wild polioviruses were isolated at the beginning and the end of the dry season. Similar RFLP patterns were observed for the 3 wild type 1 polioviruses. Comparison of partial genomic sequences in the VP1/2 A region of 1 of the wild type 1 isolates with 2 wild type strains isolated in Antananarivo in 1992 and 1993 showed a divergence of at least 10% between the strains, suggesting at least two different pathways of transmission during this period. Our findings demonstrate that immunization with 3 doses of OPV did not prevent intestinal carriage of wild poliovirus strains, and that there is a risk of wild poliovirus transmission to susceptible children in the area. Multiple strategies are required to improve immunization coverage in Madagascar. (+info)A Sabin vaccine-derived field isolate of poliovirus type 1 displaying aberrant phenotypic and genetic features, including a deletion in antigenic site 1. (4/545)
Poliovirus strains derived from the oral poliovirus vaccine (Sabin) can be differentiated from wild-type poliovirus by tests based on either immunological or genetic properties of the strains. The characterization of a recently identified poliovirus type 1 isolate with exceptional properties is described. Initial phenotypic analysis of the virus by use of polyclonal absorbed antisera suggested a wild-type character. However, the different genomic analyses all confirmed the Sabin-derived character of the virus. All 17 plaques isolated from the strain shared these properties, thus excluding the possibility of a mixture of a wild-type and a Sabin-derived strain. To elucidate the properties of this virus further, the nucleotide sequences of the P1 region and most of the 5' non-coding region were established. Although the nucleotide identity with Sabin 1 was more than 99.4%, mutations were observed in regions encoding three major antigenic sites; the deduced amino acid substitutions confirmed the aberrant results of micro-neutralization assays with site-specific monoclonal antibodies. The most striking feature was the existence of a hexanucleotide deletion in the VP1 gene, which gave rise to a two amino acid deletion in the BC loop. In spite of these antigenic changes, the strain was readily serotyped as poliovirus type 1 under standard conditions. Likewise, replication of the virus under cell culture conditions was not affected by these mutations or by the deletion. Standard polio vaccination protects against this aberrant virus, and its epidemiological significance remains open. (+info)Progress toward poliomyelitis eradication--South East Asia Region, 1997-1998. (5/545)
In 1988, the World Health Assembly resolved to eradicate poliomyelitis by 2000. To achieve this goal, in 1994 World Health Organization (WHO) South East Asia Region (SEAR) member countries accelerated implementation of polio eradication strategies. In 1994, Thailand became the region's first country to initiate National Immunization Days (NIDs), followed by Bangladesh, Bhutan, India, Indonesia, and Sri Lanka (1995); Myanmar and Nepal (1996); and Democratic People's Republic (DPR) of Korea and Maldives (1997). This report summarizes the progress in achieving routine and supplemental vaccination coverage and surveillance for cases of acute flaccid paralysis (AFP) and the impact of these activities on polio eradication in the region. (+info)Progress toward poliomyelitis eradication--Nigeria, 1996-1998. (6/545)
In 1988, the World Health Assembly resolved to eradicate poliomyelitis globally by 2000. In the African Region of the World Health Organization (WHO), eradication efforts were accelerated following supporting resolutions by WHO's Regional Committee for Africa in 1995 and the Organization of African Unity in 1996. Nigeria, the most populous country in Africa and part of a densely populated West African area extending from Nigeria to Cote D'Ivoire, is critically important to the global polio eradication initiative. This report summarizes 1) the success of National Immunization Days (NIDs); 2) the establishment of acute flaccid paralysis (AFP) surveillance; and 3) accelerated efforts to meet the 2000 target, including mopping-up planned for later in 1999. (+info)Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype. (7/545)
In this study, we attempted to identify the molecular determinants in the genome of the attenuated Sabin 2 vaccine strain of poliovirus that may change during vaccine production and result in an increase in monkey neurovirulence. An extensive search for suitable vaccine lots identified six batches that had failed the monkey neurovirulence test (MNVT). On repeated tests, these batches were found to have acceptable levels of monkey neurovirulence. One of the batches was additionally passaged six times under conditions used in vaccine production, and the resulting high-passage sample was screened for the presence of mutations and tested in monkeys. In addition to the previously described A --> G reversion at nucleotide 481, high-passage stock also contained a mutation in the VP1-coding region (3364 = G --> A) that consistently accumulated in the course of passaging. However, despite the presence of substantial amounts of these mutations, high-passage stock passed the MNVT. Replication of Sabin 2 poliovirus in the central nervous system of transgenic mice susceptible to poliovirus or in cultures of mouse cells, resulted in another mutation (3363 = A --> G). Even though its presence correlated with paralysis in mice, the introduction of 3363-G into the Sabin 2 genome did not increase neurovirulence of the virus. Previous studies identified the 481-G mutation as an important determinant of monkey neurovirulence. We prepared virus samples with varying amounts of genetically defined single mutants at this nucleotide and tested them in monkeys. The results demonstrated that even a 100% substitution at this site introduced into Sabin 2 strain did not increase monkey neurovirulence. The determination of the nucleotide sequence of an alternative strain used for the production of type 2 OPV (Chung 2) showed that it contained 100% of the wild-type 481-G but possessed an extremely low level of neurovirulence. These results demonstrate the remarkable stability of the attenuated phenotype of the Sabin 2 strain and show that (1) no batch of OPV 2 has ever repeatedly failed the MNVT, (2) growing the virus beyond the passage level allowed in vaccine production did not result in increased neurovirulence in monkeys, (3) a test for neurovirulence in transgenic mice may be more sensitive than the MNVT, and (4) determination of the mutational profile of vaccine batches detects inconsistencies in vaccine manufacturing processing that would not be detected by the MNVT. (+info)Progress toward global poliomyelitis eradication--1997-1998. (8/545)
In 1988, the World Health Assembly resolved to eradicate poliomyelitis globally by 2000. Since then, substantial progress has been reported by all countries where polio is endemic in implementing the recommended polio eradication strategies (i.e., achieving and maintaining high routine coverage with oral poliovirus vaccine [OPV]; conducting National Immunization Days [NIDs] to rapidly decrease poliovirus circulation; establishing sensitive surveillance systems for polio cases and poliovirus; and carrying out mopping-up vaccination activities to eliminate the remaining reservoirs of poliovirus transmission). Although much progress has been made in many countries, substantial obstacles remain, particularly in 14 priority countries (i.e., global reservoir countries or countries with ongoing armed internal strife or civil war). This report updates progress during 1998 toward the global eradication target and describes accelerated activities to achieve the 2000 goal. (+info)Poliovirus Vaccine, Inactivated (IPV) is a vaccine used to prevent poliomyelitis (polio), a highly infectious disease caused by the poliovirus. IPV contains inactivated (killed) polioviruses of all three poliovirus types. It works by stimulating an immune response in the body, but because the viruses are inactivated, they cannot cause polio. After vaccination, the immune system recognizes and responds to the inactivated viruses, producing antibodies that protect against future infection with wild, or naturally occurring, polioviruses. IPV is typically given as an injection in the leg or arm, and a series of doses are required for full protection. It is a safe and effective way to prevent polio and its complications.
Poliovirus Vaccine, Oral (OPV) is a vaccine used to prevent poliomyelitis (polio). It contains live attenuated (weakened) polioviruses, which stimulate an immune response in the body and provide protection against all three types of wild, infectious polioviruses. OPV is given by mouth, usually in drops, and it replicates in the gastrointestinal tract, where it induces a strong immune response. This response not only protects the individual who receives the vaccine but also helps to stop the spread of poliovirus in the community, providing indirect protection (herd immunity) to those who are not vaccinated. OPV is safe, effective, and easy to administer, making it an important tool for global polio eradication efforts. However, due to the risk of vaccine-associated paralytic polio (VAPP), inactivated poliovirus vaccine (IPV) is recommended for routine immunization in some countries.
Poliovirus is a human enterovirus, specifically a type of picornavirus, that is the causative agent of poliomyelitis (polio). It is a small, non-enveloped, single-stranded, positive-sense RNA virus. There are three serotypes of Poliovirus (types 1, 2 and 3) which can cause different degrees of severity in the disease. The virus primarily spreads through the fecal-oral route and infects the gastrointestinal tract, from where it can invade the nervous system and cause paralysis.
The Poliovirus has an icosahedral symmetry, with a diameter of about 30 nanometers. It contains a single stranded RNA genome which is encapsidated in a protein shell called capsid. The capsid is made up of 60 units of four different proteins (VP1, VP2, VP3 and VP4).
Poliovirus has been eradicated from most countries of the world through widespread vaccination with inactivated poliovirus vaccine (IPV) or oral poliovirus vaccine (OPV). However, it still remains endemic in a few countries and is considered a major public health concern.
Poliovirus vaccines are preparations used for active immunization against poliomyelitis, a highly infectious disease caused by the poliovirus. The two types of poliovirus vaccines available are:
1. Inactivated Poliovirus Vaccine (IPV): This vaccine contains inactivated (killed) poliovirus strains of all three serotypes. IPV is typically administered through an injection, usually in combination with other vaccines. It provides a strong immune response and does not carry the risk of vaccine-associated paralytic polio (VAPP), which is a rare but serious adverse event associated with the oral poliovirus vaccine (OPV).
2. Oral Poliovirus Vaccine (OPV): This vaccine contains live attenuated (weakened) poliovirus strains of all three serotypes. OPV is administered orally and induces both humoral and intestinal immunity, which helps prevent the spread of the virus in a community. However, there is a small risk of VAPP associated with this vaccine, especially after multiple doses. In rare cases, the weakened virus can revert to its virulent form and cause paralytic polio in the vaccinated individual or their close contacts.
Both IPV and OPV have been instrumental in global efforts to eradicate polio. The World Health Organization (WHO) recommends using IPV in routine immunization programs, while using OPV during supplementary immunization activities in areas with a high risk of poliovirus transmission.
Poliomyelitis, also known as polio, is a highly infectious disease caused by a virus that invades the body through the mouth, usually from contaminated water or food. The virus multiplies in the intestine and can invade the nervous system, causing paralysis.
The medical definition of Poliomyelitis includes:
1. An acute viral infection caused by the poliovirus.
2. Characterized by inflammation of the gray matter of the spinal cord (poliomyelitis), leading to muscle weakness, and in some cases, paralysis.
3. The disease primarily affects children under 5 years of age.
4. Transmission occurs through the fecal-oral route or, less frequently, by respiratory droplets.
5. The virus enters the body via the mouth, multiplies in the intestines, and can invade the nervous system.
6. There are three types of poliovirus (types 1, 2, and 3), each capable of causing paralytic polio.
7. Infection with one type does not provide immunity to the other two types.
8. The disease has no cure, but vaccination can prevent it.
9. Two types of vaccines are available: inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV).
10. Rare complications of OPV include vaccine-associated paralytic polio (VAPP) and circulating vaccine-derived polioviruses (cVDPVs).
I'm sorry for any confusion, but "Oman" is not a medical term or concept. It is the name of a country, which is located on the southeastern coast of the Arabian Peninsula in Western Asia. If you have any questions related to medicine or healthcare, I would be happy to try and help answer those for you!
Combined vaccines are defined in medical terms as vaccines that contain two or more antigens from different diseases, which are given to provide protection against multiple diseases at the same time. This approach reduces the number of injections required and simplifies the immunization schedule, especially during early childhood. Examples of combined vaccines include:
1. DTaP-Hib-IPV (e.g., Pentacel): A vaccine that combines diphtheria, tetanus, pertussis (whooping cough), Haemophilus influenzae type b (Hib) disease, and poliovirus components in one injection to protect against these five diseases.
2. MMRV (e.g., ProQuad): A vaccine that combines measles, mumps, rubella, and varicella (chickenpox) antigens in a single injection to provide immunity against all four diseases.
3. HepA-HepB (e.g., Twinrix): A vaccine that combines hepatitis A and hepatitis B antigens in one injection, providing protection against both types of hepatitis.
4. MenACWY-TT (e.g., MenQuadfi): A vaccine that combines four serogroups of meningococcal bacteria (A, C, W, Y) with tetanus toxoid as a carrier protein in one injection for the prevention of invasive meningococcal disease caused by these serogroups.
5. PCV13-PPSV23 (e.g., Vaxneuvance): A vaccine that combines 13 pneumococcal serotypes with PPSV23, providing protection against a broader range of pneumococcal diseases in adults aged 18 years and older.
Combined vaccines have been thoroughly tested for safety and efficacy to ensure they provide a strong immune response and an acceptable safety profile. They are essential tools in preventing various infectious diseases and improving overall public health.
Inactivated vaccines, also known as killed or non-live vaccines, are created by using a version of the virus or bacteria that has been grown in a laboratory and then killed or inactivated with chemicals, heat, or radiation. This process renders the organism unable to cause disease, but still capable of stimulating an immune response when introduced into the body.
Inactivated vaccines are generally considered safer than live attenuated vaccines since they cannot revert back to a virulent form and cause illness. However, they may require multiple doses or booster shots to maintain immunity because the immune response generated by inactivated vaccines is not as robust as that produced by live vaccines. Examples of inactivated vaccines include those for hepatitis A, rabies, and influenza (inactivated flu vaccine).
An immunization schedule is a series of planned dates when a person, usually a child, should receive specific vaccines in order to be fully protected against certain preventable diseases. The schedule is developed based on scientific research and recommendations from health organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC).
The immunization schedule outlines which vaccines are recommended, the number of doses required, the age at which each dose should be given, and the minimum amount of time that must pass between doses. The schedule may vary depending on factors such as the individual's age, health status, and travel plans.
Immunization schedules are important for ensuring that individuals receive timely protection against vaccine-preventable diseases, and for maintaining high levels of immunity in populations, which helps to prevent the spread of disease. It is important to follow the recommended immunization schedule as closely as possible to ensure optimal protection.
A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. It typically contains an agent that resembles the disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it encounters in the future.
Vaccines can be prophylactic (to prevent or ameliorate the effects of a future infection by a natural or "wild" pathogen), or therapeutic (to fight disease that is already present). The administration of vaccines is called vaccination. Vaccinations are generally administered through needle injections, but can also be administered by mouth or sprayed into the nose.
The term "vaccine" comes from Edward Jenner's 1796 use of cowpox to create immunity to smallpox. The first successful vaccine was developed in 1796 by Edward Jenner, who showed that milkmaids who had contracted cowpox did not get smallpox. He reasoned that exposure to cowpox protected against smallpox and tested his theory by injecting a boy with pus from a cowpox sore and then exposing him to smallpox, which the boy did not contract. The word "vaccine" is derived from Variolae vaccinae (smallpox of the cow), the term devised by Jenner to denote cowpox. He used it in 1798 during a conversation with a fellow physician and later in the title of his 1801 Inquiry.
Vaccination is a simple, safe, and effective way to protect people against harmful diseases, before they come into contact with them. It uses your body's natural defenses to build protection to specific infections and makes your immune system stronger.
A vaccination usually contains a small, harmless piece of a virus or bacteria (or toxins produced by these germs) that has been made inactive or weakened so it won't cause the disease itself. This piece of the germ is known as an antigen. When the vaccine is introduced into the body, the immune system recognizes the antigen as foreign and produces antibodies to fight it.
If a person then comes into contact with the actual disease-causing germ, their immune system will recognize it and immediately produce antibodies to destroy it. The person is therefore protected against that disease. This is known as active immunity.
Vaccinations are important for both individual and public health. They prevent the spread of contagious diseases and protect vulnerable members of the population, such as young children, the elderly, and people with weakened immune systems who cannot be vaccinated or for whom vaccination is not effective.
Virus shedding refers to the release of virus particles by an infected individual, who can then transmit the virus to others through various means such as respiratory droplets, fecal matter, or bodily fluids. This occurs when the virus replicates inside the host's cells and is released into the surrounding environment, where it can infect other individuals. The duration of virus shedding varies depending on the specific virus and the individual's immune response. It's important to note that some individuals may shed viruses even before they show symptoms, making infection control measures such as hand hygiene, mask-wearing, and social distancing crucial in preventing the spread of infectious diseases.
Immunization programs, also known as vaccination programs, are organized efforts to administer vaccines to populations or communities in order to protect individuals from vaccine-preventable diseases. These programs are typically implemented by public health agencies and involve the planning, coordination, and delivery of immunizations to ensure that a high percentage of people are protected against specific infectious diseases.
Immunization programs may target specific age groups, such as infants and young children, or populations at higher risk of certain diseases, such as travelers, healthcare workers, or individuals with weakened immune systems. The goals of immunization programs include controlling and eliminating vaccine-preventable diseases, reducing the morbidity and mortality associated with these diseases, and protecting vulnerable populations from outbreaks and epidemics.
Immunization programs may be delivered through a variety of settings, including healthcare facilities, schools, community centers, and mobile clinics. They often involve partnerships between government agencies, healthcare providers, non-governmental organizations, and communities to ensure that vaccines are accessible, affordable, and acceptable to the populations they serve. Effective immunization programs require strong leadership, adequate funding, robust data systems, and ongoing monitoring and evaluation to assess their impact and identify areas for improvement.
A jet injection is a type of medical injection that uses a high-pressure stream of medication to deliver the dose through the skin and into the underlying tissue. This method does not require the use of a hypodermic needle and is also known as a "needle-free" injection. Jet injectors have been used for various purposes, including vaccination, pain management, and treatment of some skin conditions. However, their use has declined in recent years due to concerns about potential safety issues, such as the risk of cross-contamination between patients and the possibility of injury to the tissue.
Antibodies, viral are proteins produced by the immune system in response to an infection with a virus. These antibodies are capable of recognizing and binding to specific antigens on the surface of the virus, which helps to neutralize or destroy the virus and prevent its replication. Once produced, these antibodies can provide immunity against future infections with the same virus.
Viral antibodies are typically composed of four polypeptide chains - two heavy chains and two light chains - that are held together by disulfide bonds. The binding site for the antigen is located at the tip of the Y-shaped structure, formed by the variable regions of the heavy and light chains.
There are five classes of antibodies in humans: IgA, IgD, IgE, IgG, and IgM. Each class has a different function and is distributed differently throughout the body. For example, IgG is the most common type of antibody found in the bloodstream and provides long-term immunity against viruses, while IgA is found primarily in mucous membranes and helps to protect against respiratory and gastrointestinal infections.
In addition to their role in the immune response, viral antibodies can also be used as diagnostic tools to detect the presence of a specific virus in a patient's blood or other bodily fluids.
A viral vaccine is a biological preparation that introduces your body to a specific virus in a way that helps your immune system build up protection against the virus without causing the illness. Viral vaccines can be made from weakened or inactivated forms of the virus, or parts of the virus such as proteins or sugars. Once introduced to the body, the immune system recognizes the virus as foreign and produces an immune response, including the production of antibodies. These antibodies remain in the body and provide immunity against future infection with that specific virus.
Viral vaccines are important tools for preventing infectious diseases caused by viruses, such as influenza, measles, mumps, rubella, polio, hepatitis A and B, rabies, rotavirus, chickenpox, shingles, and some types of cancer. Vaccination programs have led to the control or elimination of many infectious diseases that were once common.
It's important to note that viral vaccines are not effective against bacterial infections, and separate vaccines must be developed for each type of virus. Additionally, because viruses can mutate over time, it is necessary to update some viral vaccines periodically to ensure continued protection.
The Diphtheria-Tetanus-Pertussis (DTaP) vaccine is a combination immunization that protects against three bacterial diseases: diphtheria, tetanus (lockjaw), and pertussis (whooping cough).
Diphtheria is an upper respiratory infection that can lead to breathing difficulties, heart failure, paralysis, or even death. Tetanus is a bacterial infection that affects the nervous system and causes muscle stiffness and spasms, leading to "lockjaw." Pertussis is a highly contagious respiratory infection characterized by severe coughing fits, which can make it difficult to breathe and may lead to pneumonia, seizures, or brain damage.
The DTaP vaccine contains inactivated toxins (toxoids) from the bacteria that cause these diseases. It is typically given as a series of five shots, with doses administered at 2 months, 4 months, 6 months, 15-18 months, and 4-6 years of age. The vaccine helps the immune system develop protection against the diseases without causing the actual illness.
It is important to note that there are other combination vaccines available that protect against these same diseases, such as DT (diphtheria and tetanus toxoids) and Tdap (tetanus, diphtheria, and acellular pertussis), which contain higher doses of the diphtheria and pertussis components. These vaccines are recommended for different age groups and may be used as booster shots to maintain immunity throughout adulthood.
Diphtheria-Tetanus-acellular Pertussis (DTaP) vaccines are a type of combination vaccine that protect against three serious diseases caused by bacteria: diphtheria, tetanus, and pertussis (also known as whooping cough).
Diphtheria is a highly contagious respiratory infection that can cause breathing difficulties, heart failure, paralysis, and even death. Tetanus, also known as lockjaw, is a bacterial infection that affects the nervous system and causes muscle stiffness and spasms, which can be severe enough to cause broken bones or suffocation. Pertussis is a highly contagious respiratory infection that causes severe coughing fits, making it difficult to breathe, eat, or drink.
The "a" in DTaP stands for "acellular," which means that the pertussis component of the vaccine contains only parts of the bacteria, rather than the whole cells used in older vaccines. This reduces the risk of side effects associated with the whole-cell pertussis vaccine while still providing effective protection against the disease.
DTaP vaccines are typically given as a series of five shots, starting at 2 months of age and ending at 4-6 years of age. Booster doses may be recommended later in life to maintain immunity. DTaP vaccines are an essential part of routine childhood immunization schedules and have significantly reduced the incidence of these diseases worldwide.
Synthetic vaccines are artificially produced, designed to stimulate an immune response and provide protection against specific diseases. Unlike traditional vaccines that are derived from weakened or killed pathogens, synthetic vaccines are created using synthetic components, such as synthesized viral proteins, DNA, or RNA. These components mimic the disease-causing agent and trigger an immune response without causing the actual disease. The use of synthetic vaccines offers advantages in terms of safety, consistency, and scalability in production, making them valuable tools for preventing infectious diseases.
I could not find a specific medical definition for "Vaccines, DNA." However, I can provide you with some information about DNA vaccines.
DNA vaccines are a type of vaccine that uses genetically engineered DNA to stimulate an immune response in the body. They work by introducing a small piece of DNA into the body that contains the genetic code for a specific antigen (a substance that triggers an immune response). The cells of the body then use this DNA to produce the antigen, which prompts the immune system to recognize and attack it.
DNA vaccines have several advantages over traditional vaccines. They are relatively easy to produce, can be stored at room temperature, and can be designed to protect against a wide range of diseases. Additionally, because they use DNA to stimulate an immune response, DNA vaccines do not require the growth and culture of viruses or bacteria, which can make them safer than traditional vaccines.
DNA vaccines are still in the experimental stages, and more research is needed to determine their safety and effectiveness. However, they have shown promise in animal studies and are being investigated as a potential tool for preventing a variety of infectious diseases, including influenza, HIV, and cancer.
Bacterial vaccines are types of vaccines that are created using bacteria or parts of bacteria as the immunogen, which is the substance that triggers an immune response in the body. The purpose of a bacterial vaccine is to stimulate the immune system to develop protection against specific bacterial infections.
There are several types of bacterial vaccines, including:
1. Inactivated or killed whole-cell vaccines: These vaccines contain entire bacteria that have been killed or inactivated through various methods, such as heat or chemicals. The bacteria can no longer cause disease, but they still retain the ability to stimulate an immune response.
2. Subunit, protein, or polysaccharide vaccines: These vaccines use specific components of the bacterium, such as proteins or polysaccharides, that are known to trigger an immune response. By using only these components, the vaccine can avoid using the entire bacterium, which may reduce the risk of adverse reactions.
3. Live attenuated vaccines: These vaccines contain live bacteria that have been weakened or attenuated so that they cannot cause disease but still retain the ability to stimulate an immune response. This type of vaccine can provide long-lasting immunity, but it may not be suitable for people with weakened immune systems.
Bacterial vaccines are essential tools in preventing and controlling bacterial infections, reducing the burden of diseases such as tuberculosis, pneumococcal disease, meningococcal disease, and Haemophilus influenzae type b (Hib) disease. They work by exposing the immune system to a harmless form of the bacteria or its components, which triggers the production of antibodies and memory cells that can recognize and fight off future infections with that same bacterium.
It's important to note that while vaccines are generally safe and effective, they may cause mild side effects such as pain, redness, or swelling at the injection site, fever, or fatigue. Serious side effects are rare but can occur, so it's essential to consult with a healthcare provider before receiving any vaccine.
Secondary immunization, also known as "anamnestic response" or "booster," refers to the enhanced immune response that occurs upon re-exposure to an antigen, having previously been immunized or infected with the same pathogen. This response is characterized by a more rapid and robust production of antibodies and memory cells compared to the primary immune response. The secondary immunization aims to maintain long-term immunity against infectious diseases and improve vaccine effectiveness. It usually involves administering additional doses of a vaccine or booster shots after the initial series of immunizations, which helps reinforce the immune system's ability to recognize and combat specific pathogens.
Drug contamination refers to the presence of impurities or foreign substances in a pharmaceutical drug or medication. These impurities can include things like bacteria, chemicals, or other drugs that are not intended to be present in the final product. Drug contamination can occur at any stage during the production, storage, or distribution of a medication and can potentially lead to reduced effectiveness, increased side effects, or serious health risks for patients. It is closely monitored and regulated by various health authorities to ensure the safety and efficacy of medications.
Haemophilus vaccines are vaccines that are designed to protect against Haemophilus influenzae type b (Hib), a bacterium that can cause serious infections such as meningitis, pneumonia, and epiglottitis. There are two main types of Hib vaccines:
1. Polysaccharide vaccine: This type of vaccine is made from the sugar coating (polysaccharide) of the bacterial cells. It is not effective in children under 2 years of age because their immune systems are not yet mature enough to respond effectively to this type of vaccine.
2. Conjugate vaccine: This type of vaccine combines the polysaccharide with a protein carrier, which helps to stimulate a stronger and more sustained immune response. It is effective in infants as young as 6 weeks old.
Hib vaccines are usually given as part of routine childhood immunizations starting at 2 months of age. They are administered through an injection into the muscle. The vaccine is safe and effective, with few side effects. Vaccination against Hib has led to a significant reduction in the incidence of Hib infections worldwide.
An AIDS vaccine is a type of preventive vaccine that aims to stimulate the immune system to produce an effective response against the human immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome (AIDS). The goal of an AIDS vaccine is to induce the production of immune cells and proteins that can recognize and eliminate HIV-infected cells, thereby preventing the establishment of a persistent infection.
Despite decades of research, there is still no licensed AIDS vaccine available. This is due in part to the unique challenges posed by HIV, which has a high mutation rate and can rapidly evolve to evade the immune system's defenses. However, several promising vaccine candidates are currently being tested in clinical trials around the world, and researchers continue to explore new approaches and strategies for developing an effective AIDS vaccine.
I am not aware of a specific medical definition for "Cuba." Cuba is actually a country, specifically an island nation located in the Caribbean Sea. It is south of Florida and the Bahamas, west of Haiti, and north of Jamaica. The term "Cuba" would not typically be used in a medical context unless it was referring to something or someone that is related to or originates from this country. For example, a "Cuban immigrant" might be mentioned in a medical history, or a patient might have traveled to Cuba for medical treatment. In these cases, the relevant medical information would relate to the individual's personal history or the specific medical care they received, rather than to any inherent qualities of the country itself.
Attenuated vaccines consist of live microorganisms that have been weakened (attenuated) through various laboratory processes so they do not cause disease in the majority of recipients but still stimulate an immune response. The purpose of attenuation is to reduce the virulence or replication capacity of the pathogen while keeping it alive, allowing it to retain its antigenic properties and induce a strong and protective immune response.
Examples of attenuated vaccines include:
1. Sabin oral poliovirus vaccine (OPV): This vaccine uses live but weakened polioviruses to protect against all three strains of the disease-causing poliovirus. The weakened viruses replicate in the intestine and induce an immune response, which provides both humoral (antibody) and cell-mediated immunity.
2. Measles, mumps, and rubella (MMR) vaccine: This combination vaccine contains live attenuated measles, mumps, and rubella viruses. It is given to protect against these three diseases and prevent their spread in the population.
3. Varicella (chickenpox) vaccine: This vaccine uses a weakened form of the varicella-zoster virus, which causes chickenpox. By introducing this attenuated virus into the body, it stimulates an immune response that protects against future infection with the wild-type virus.
4. Yellow fever vaccine: This live attenuated vaccine is used to prevent yellow fever, a viral disease transmitted by mosquitoes in tropical and subtropical regions of Africa and South America. The vaccine contains a weakened form of the yellow fever virus that cannot cause the disease but still induces an immune response.
5. Bacillus Calmette-Guérin (BCG) vaccine: This live attenuated vaccine is used to protect against tuberculosis (TB). It contains a weakened strain of Mycobacterium bovis, which does not cause TB in humans but stimulates an immune response that provides some protection against the disease.
Attenuated vaccines are generally effective at inducing long-lasting immunity and can provide robust protection against targeted diseases. However, they may pose a risk for individuals with weakened immune systems, as the attenuated viruses or bacteria could potentially cause illness in these individuals. Therefore, it is essential to consider an individual's health status before administering live attenuated vaccines.
I am not aware of any medical definition for the term "Egypt." Egypt is a country located in the northeastern corner of Africa, known for its rich history and cultural heritage. It is home to various ancient artifacts and monuments, including the Pyramids of Giza and the Sphinx.
If you have any specific medical or health-related questions related to Egypt, such as information about diseases prevalent in the country or healthcare practices there, I would be happy to try to help answer those for you.
Paralysis is a loss of muscle function in part or all of your body. It can be localized, affecting only one specific area, or generalized, impacting multiple areas or even the entire body. Paralysis often occurs when something goes wrong with the way messages pass between your brain and muscles. In most cases, paralysis is caused by damage to the nervous system, especially the spinal cord. Other causes include stroke, trauma, infections, and various neurological disorders.
It's important to note that paralysis doesn't always mean a total loss of movement or feeling. Sometimes, it may just cause weakness or numbness in the affected area. The severity and extent of paralysis depend on the underlying cause and the location of the damage in the nervous system.
"Hepatitis B vaccines are vaccines that prevent infection caused by the hepatitis B virus. They work by introducing a small and harmless piece of the virus to your body, which triggers your immune system to produce antibodies to fight off the infection. These antibodies remain in your body and provide protection if you are exposed to the real hepatitis B virus in the future.
The hepatitis B vaccine is typically given as a series of three shots over a six-month period. It is recommended for all infants, children and adolescents who have not previously been vaccinated, as well as for adults who are at increased risk of infection, such as healthcare workers, people who inject drugs, and those with certain medical conditions.
It's important to note that hepatitis B vaccine does not provide protection against other types of viral hepatitis, such as hepatitis A or C."
Feces are the solid or semisolid remains of food that could not be digested or absorbed in the small intestine, along with bacteria and other waste products. After being stored in the colon, feces are eliminated from the body through the rectum and anus during defecation. Feces can vary in color, consistency, and odor depending on a person's diet, health status, and other factors.
Conjugate vaccines are a type of vaccine that combines a part of a bacterium with a protein or other substance to boost the body's immune response to the bacteria. The bacterial component is usually a polysaccharide, which is a long chain of sugars that makes up part of the bacterial cell wall.
By itself, a polysaccharide is not very immunogenic, meaning it does not stimulate a strong immune response. However, when it is conjugated or linked to a protein or other carrier molecule, it becomes much more immunogenic and can elicit a stronger and longer-lasting immune response.
Conjugate vaccines are particularly effective in protecting against bacterial infections that affect young children, such as Haemophilus influenzae type b (Hib) and pneumococcal disease. These vaccines have been instrumental in reducing the incidence of these diseases and their associated complications, such as meningitis and pneumonia.
Overall, conjugate vaccines work by mimicking a natural infection and stimulating the immune system to produce antibodies that can protect against future infections with the same bacterium. By combining a weakly immunogenic polysaccharide with a protein carrier, these vaccines can elicit a stronger and more effective immune response, providing long-lasting protection against bacterial infections.
A subunit vaccine is a type of vaccine that contains a specific piece or component of the microorganism (such as a protein, sugar, or part of the bacterial outer membrane), instead of containing the entire organism. This piece of the microorganism is known as an antigen, and it stimulates an immune response in the body, allowing the development of immunity against the targeted infection without introducing the risk of disease associated with live vaccines.
Subunit vaccines offer several advantages over other types of vaccines. They are generally safer because they do not contain live or weakened microorganisms, making them suitable for individuals with weakened immune systems or specific medical conditions that prevent them from receiving live vaccines. Additionally, subunit vaccines can be designed to focus on the most immunogenic components of a pathogen, potentially leading to stronger and more targeted immune responses.
Examples of subunit vaccines include the Hepatitis B vaccine, which contains a viral protein, and the Haemophilus influenzae type b (Hib) vaccine, which uses pieces of the bacterial polysaccharide capsule. These vaccines have been crucial in preventing serious infectious diseases and reducing associated complications worldwide.
Sewage is not typically considered a medical term, but it does have relevance to public health and medicine. Sewage is the wastewater that is produced by households and industries, which contains a variety of contaminants including human waste, chemicals, and other pollutants. It can contain various pathogens such as bacteria, viruses, and parasites, which can cause diseases in humans if they come into contact with it or consume contaminated food or water. Therefore, the proper treatment and disposal of sewage is essential to prevent the spread of infectious diseases and protect public health.
Neutralization tests are a type of laboratory assay used in microbiology and immunology to measure the ability of a substance, such as an antibody or antitoxin, to neutralize the activity of a toxin or infectious agent. In these tests, the substance to be tested is mixed with a known quantity of the toxin or infectious agent, and the mixture is then incubated under controlled conditions. After incubation, the mixture is tested for residual toxicity or infectivity using a variety of methods, such as cell culture assays, animal models, or biochemical assays.
The neutralization titer is then calculated based on the highest dilution of the test substance that completely neutralizes the toxin or infectious agent. Neutralization tests are commonly used in the diagnosis and evaluation of immune responses to vaccines, as well as in the detection and quantification of toxins and other harmful substances.
Examples of neutralization tests include the serum neutralization test for measles antibodies, the plaque reduction neutralization test (PRNT) for dengue virus antibodies, and the cytotoxicity neutralization assay for botulinum neurotoxins.
'Afghanistan' is a country and not a medical term or condition. It is located in Central Asia and is bordered by Pakistan, Iran, Turkmenistan, Uzbekistan, Tajikistan, China, and the Arabian Sea. The country has a complex history with ongoing political and security challenges. If you are looking for information related to medical tourism or healthcare in Afghanistan, I can provide some general insights. However, please note that the medical facilities and services in Afghanistan may not be comparable to those in developed countries due to various factors such as infrastructure, resources, and expertise.
A viral RNA (ribonucleic acid) is the genetic material found in certain types of viruses, as opposed to viruses that contain DNA (deoxyribonucleic acid). These viruses are known as RNA viruses. The RNA can be single-stranded or double-stranded and can exist as several different forms, such as positive-sense, negative-sense, or ambisense RNA. Upon infecting a host cell, the viral RNA uses the host's cellular machinery to translate the genetic information into proteins, leading to the production of new virus particles and the continuation of the viral life cycle. Examples of human diseases caused by RNA viruses include influenza, COVID-19 (SARS-CoV-2), hepatitis C, and polio.
Mass vaccination is a coordinated effort to administer vaccine doses to a large portion of a population in a short amount of time. This strategy is often used during outbreaks of infectious diseases, such as influenza or measles, to quickly build up community immunity (herd immunity) and reduce the spread of the disease. Mass vaccination campaigns can also be implemented as part of public health initiatives to control or eliminate vaccine-preventable diseases in a population. These campaigns typically involve mobilizing healthcare workers, volunteers, and resources to reach and vaccinate as many people as possible, often through mobile clinics, community centers, and other accessible locations.
An "injection, intradermal" refers to a type of injection where a small quantity of a substance is introduced into the layer of skin between the epidermis and dermis, using a thin gauge needle. This technique is often used for diagnostic or research purposes, such as conducting allergy tests or administering immunizations in a way that stimulates a strong immune response. The injection site typically produces a small, raised bump (wheal) that disappears within a few hours. It's important to note that intradermal injections should be performed by trained medical professionals to minimize the risk of complications.
Malaria vaccines are biological preparations that induce immunity against malaria parasites, thereby preventing or reducing the severity of malaria disease. They typically contain antigens (proteins or other molecules derived from the parasite) that stimulate an immune response in the recipient, enabling their body to recognize and neutralize the pathogen upon exposure.
The most advanced malaria vaccine candidate is RTS,S/AS01 (Mosquirix), which targets the Plasmodium falciparum parasite's circumsporozoite protein (CSP). This vaccine has shown partial protection in clinical trials, reducing the risk of severe malaria and hospitalization in young children by about 30% over four years. However, it does not provide complete immunity, and additional research is ongoing to develop more effective vaccines against malaria.
A disease outbreak is defined as the occurrence of cases of a disease in excess of what would normally be expected in a given time and place. It may affect a small and localized group or a large number of people spread over a wide area, even internationally. An outbreak may be caused by a new agent, a change in the agent's virulence or host susceptibility, or an increase in the size or density of the host population.
Outbreaks can have significant public health and economic impacts, and require prompt investigation and control measures to prevent further spread of the disease. The investigation typically involves identifying the source of the outbreak, determining the mode of transmission, and implementing measures to interrupt the chain of infection. This may include vaccination, isolation or quarantine, and education of the public about the risks and prevention strategies.
Examples of disease outbreaks include foodborne illnesses linked to contaminated food or water, respiratory infections spread through coughing and sneezing, and mosquito-borne diseases such as Zika virus and West Nile virus. Outbreaks can also occur in healthcare settings, such as hospitals and nursing homes, where vulnerable populations may be at increased risk of infection.
"Intramuscular injections" refer to a medical procedure where a medication or vaccine is administered directly into the muscle tissue. This is typically done using a hypodermic needle and syringe, and the injection is usually given into one of the large muscles in the body, such as the deltoid (shoulder), vastus lateralis (thigh), or ventrogluteal (buttock) muscles.
Intramuscular injections are used for a variety of reasons, including to deliver medications that need to be absorbed slowly over time, to bypass stomach acid and improve absorption, or to ensure that the medication reaches the bloodstream quickly and directly. Common examples of medications delivered via intramuscular injection include certain vaccines, antibiotics, and pain relievers.
It is important to follow proper technique when administering intramuscular injections to minimize pain and reduce the risk of complications such as infection or injury to surrounding tissues. Proper site selection, needle length and gauge, and injection technique are all critical factors in ensuring a safe and effective intramuscular injection.
Papillomavirus vaccines are vaccines that have been developed to prevent infection by human papillomaviruses (HPV). HPV is a DNA virus that is capable of infecting the skin and mucous membranes. Certain types of HPV are known to cause cervical cancer, as well as other types of cancer such as anal, penile, vulvar, and oropharyngeal cancers. Other types of HPV can cause genital warts.
There are currently two papillomavirus vaccines that have been approved for use in the United States: Gardasil and Cervarix. Both vaccines protect against the two most common cancer-causing types of HPV (types 16 and 18), which together cause about 70% of cervical cancers. Gardasil also protects against the two most common types of HPV that cause genital warts (types 6 and 11).
Papillomavirus vaccines are given as a series of three shots over a period of six months. They are most effective when given to people before they become sexually active, as this reduces the risk of exposure to HPV. The Centers for Disease Control and Prevention (CDC) recommends that all boys and girls get vaccinated against HPV at age 11 or 12, but the vaccine can be given to people as young as age 9 and as old as age 26.
It is important to note that papillomavirus vaccines do not protect against all types of HPV, and they do not treat existing HPV infections or cervical cancer. They are intended to prevent new HPV infections and the cancers and other diseases that can be caused by HPV.
Capsid proteins are the structural proteins that make up the capsid, which is the protective shell of a virus. The capsid encloses the viral genome and helps to protect it from degradation and detection by the host's immune system. Capsid proteins are typically arranged in a symmetrical pattern and can self-assemble into the capsid structure when exposed to the viral genome.
The specific arrangement and composition of capsid proteins vary between different types of viruses, and they play important roles in the virus's life cycle, including recognition and binding to host cells, entry into the cell, and release of the viral genome into the host cytoplasm. Capsid proteins can also serve as targets for antiviral therapies and vaccines.
Meningococcal vaccines are vaccines that protect against Neisseria meningitidis, a type of bacteria that can cause serious infections such as meningitis (inflammation of the lining of the brain and spinal cord) and septicemia (bloodstream infection). There are several types of meningococcal vaccines available, including conjugate vaccines and polysaccharide vaccines. These vaccines work by stimulating the immune system to produce antibodies that can protect against the different serogroups of N. meningitidis, including A, B, C, Y, and W-135. The specific type of vaccine used and the number of doses required may depend on a person's age, health status, and other factors. Meningococcal vaccines are recommended for certain high-risk populations, such as infants, young children, adolescents, and people with certain medical conditions, as well as for travelers to areas where meningococcal disease is common.
HeLa cells are a type of immortalized cell line used in scientific research. They are derived from a cancer that developed in the cervical tissue of Henrietta Lacks, an African-American woman, in 1951. After her death, cells taken from her tumor were found to be capable of continuous division and growth in a laboratory setting, making them an invaluable resource for medical research.
HeLa cells have been used in a wide range of scientific studies, including research on cancer, viruses, genetics, and drug development. They were the first human cell line to be successfully cloned and are able to grow rapidly in culture, doubling their population every 20-24 hours. This has made them an essential tool for many areas of biomedical research.
It is important to note that while HeLa cells have been instrumental in numerous scientific breakthroughs, the story of their origin raises ethical questions about informed consent and the use of human tissue in research.
Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.
Mucosal immunity refers to the immune system's defense mechanisms that are specifically adapted to protect the mucous membranes, which line various body openings such as the respiratory, gastrointestinal, and urogenital tracts. These membranes are constantly exposed to foreign substances, including potential pathogens, and therefore require a specialized immune response to maintain homeostasis and prevent infection.
Mucosal immunity is primarily mediated by secretory IgA (SIgA) antibodies, which are produced by B cells in the mucosa-associated lymphoid tissue (MALT). These antibodies can neutralize pathogens and prevent them from adhering to and invading the epithelial cells that line the mucous membranes.
In addition to SIgA, other components of the mucosal immune system include innate immune cells such as macrophages, dendritic cells, and neutrophils, which can recognize and respond to pathogens through pattern recognition receptors (PRRs). T cells also play a role in mucosal immunity, particularly in the induction of cell-mediated immunity against viruses and other intracellular pathogens.
Overall, mucosal immunity is an essential component of the body's defense system, providing protection against a wide range of potential pathogens while maintaining tolerance to harmless antigens present in the environment.
A measles vaccine is a biological preparation that induces immunity against the measles virus. It contains an attenuated (weakened) strain of the measles virus, which stimulates the immune system to produce antibodies that protect against future infection with the wild-type (disease-causing) virus. Measles vaccines are typically administered in combination with vaccines against mumps and rubella (German measles), forming the MMR vaccine.
The measles vaccine is highly effective, with one or two doses providing immunity in over 95% of people who receive it. It is usually given to children as part of routine childhood immunization programs, with the first dose administered at 12-15 months of age and the second dose at 4-6 years of age.
Measles vaccination has led to a dramatic reduction in the incidence of measles worldwide and is considered one of the greatest public health achievements of the past century. However, despite widespread availability of the vaccine, measles remains a significant cause of morbidity and mortality in some parts of the world, particularly in areas with low vaccination coverage or where access to healthcare is limited.
A newborn infant is a baby who is within the first 28 days of life. This period is also referred to as the neonatal period. Newborns require specialized care and attention due to their immature bodily systems and increased vulnerability to various health issues. They are closely monitored for signs of well-being, growth, and development during this critical time.
Antibody formation, also known as humoral immune response, is the process by which the immune system produces proteins called antibodies in response to the presence of a foreign substance (antigen) in the body. This process involves several steps:
1. Recognition: The antigen is recognized and bound by a type of white blood cell called a B lymphocyte or B cell, which then becomes activated.
2. Differentiation: The activated B cell undergoes differentiation to become a plasma cell, which is a type of cell that produces and secretes large amounts of antibodies.
3. Antibody production: The plasma cells produce and release antibodies, which are proteins made up of four polypeptide chains (two heavy chains and two light chains) arranged in a Y-shape. Each antibody has two binding sites that can recognize and bind to specific regions on the antigen called epitopes.
4. Neutralization or elimination: The antibodies bind to the antigens, neutralizing them or marking them for destruction by other immune cells. This helps to prevent the spread of infection and protect the body from harmful substances.
Antibody formation is an important part of the adaptive immune response, which allows the body to specifically recognize and respond to a wide variety of pathogens and foreign substances.
A viral genome is the genetic material (DNA or RNA) that is present in a virus. It contains all the genetic information that a virus needs to replicate itself and infect its host. The size and complexity of viral genomes can vary greatly, ranging from a few thousand bases to hundreds of thousands of bases. Some viruses have linear genomes, while others have circular genomes. The genome of a virus also contains the information necessary for the virus to hijack the host cell's machinery and use it to produce new copies of the virus. Understanding the genetic makeup of viruses is important for developing vaccines and antiviral treatments.
An antigen is any substance that can stimulate an immune response, particularly the production of antibodies. Viral antigens are antigens that are found on or produced by viruses. They can be proteins, glycoproteins, or carbohydrates present on the surface or inside the viral particle.
Viral antigens play a crucial role in the immune system's recognition and response to viral infections. When a virus infects a host cell, it may display its antigens on the surface of the infected cell. This allows the immune system to recognize and target the infected cells for destruction, thereby limiting the spread of the virus.
Viral antigens are also important targets for vaccines. Vaccines typically work by introducing a harmless form of a viral antigen to the body, which then stimulates the production of antibodies and memory T-cells that can recognize and respond quickly and effectively to future infections with the actual virus.
It's worth noting that different types of viruses have different antigens, and these antigens can vary between strains of the same virus. This is why there are often different vaccines available for different viral diseases, and why flu vaccines need to be updated every year to account for changes in the circulating influenza virus strains.
A Pertussis vaccine is a type of immunization used to protect against pertussis, also known as whooping cough. It contains components that stimulate the immune system to produce antibodies against the bacteria that cause pertussis, Bordetella pertussis. There are two main types of pertussis vaccines: whole-cell pertussis (wP) vaccines and acellular pertussis (aP) vaccines. wP vaccines contain killed whole cells of B. pertussis, while aP vaccines contain specific components of the bacteria, such as pertussis toxin and other antigens. Pertussis vaccines are often combined with diphtheria and tetanus to form combination vaccines, such as DTaP (diphtheria, tetanus, and acellular pertussis) and TdaP (tetanus, diphtheria, and acellular pertussis). These vaccines are typically given to young children as part of their routine immunization schedule.
"World Health" is not a term that has a specific medical definition. However, it is often used in the context of global health, which can be defined as:
"The area of study, research and practice that places a priority on improving health and achieving equity in health for all people worldwide. It emphasizes trans-national health issues, determinants, and solutions; involves many disciplines within and beyond the health sciences and engages stakeholders from across sectors and societies." (World Health Organization)
Therefore, "world health" could refer to the overall health status and health challenges faced by populations around the world. It encompasses a broad range of factors that affect the health of individuals and communities, including social, economic, environmental, and political determinants. The World Health Organization (WHO) plays a key role in monitoring and promoting global health, setting international standards and guidelines, and coordinating responses to global health emergencies.
Virulence, in the context of medicine and microbiology, refers to the degree or severity of damage or harm that a pathogen (like a bacterium, virus, fungus, or parasite) can cause to its host. It is often associated with the ability of the pathogen to invade and damage host tissues, evade or suppress the host's immune response, replicate within the host, and spread between hosts.
Virulence factors are the specific components or mechanisms that contribute to a pathogen's virulence, such as toxins, enzymes, adhesins, and capsules. These factors enable the pathogen to establish an infection, cause tissue damage, and facilitate its transmission between hosts. The overall virulence of a pathogen can be influenced by various factors, including host susceptibility, environmental conditions, and the specific strain or species of the pathogen.
BCG (Bacillus Calmette-Guérin) vaccine is a type of immunization used primarily to prevent tuberculosis (TB). It contains a live but weakened strain of Mycobacterium bovis, which is related to the bacterium that causes TB in humans (Mycobacterium tuberculosis).
The BCG vaccine works by stimulating an immune response in the body, enabling it to better resist infection with TB bacteria if exposed in the future. It is often given to infants and children in countries where TB is common, and its use varies depending on the national immunization policies. The protection offered by the BCG vaccine is moderate and may not last for a very long time.
In addition to its use against TB, the BCG vaccine has also been investigated for its potential therapeutic role in treating bladder cancer and some other types of cancer. The mechanism of action in these cases is thought to be related to the vaccine's ability to stimulate an immune response against abnormal cells.
A base sequence in the context of molecular biology refers to the specific order of nucleotides in a DNA or RNA molecule. In DNA, these nucleotides are adenine (A), guanine (G), cytosine (C), and thymine (T). In RNA, uracil (U) takes the place of thymine. The base sequence contains genetic information that is transcribed into RNA and ultimately translated into proteins. It is the exact order of these bases that determines the genetic code and thus the function of the DNA or RNA molecule.
Rabies vaccines are medical products that contain antigens of the rabies virus, which stimulate an immune response in individuals who receive them. The purpose of rabies vaccines is to prevent the development of rabies, a viral disease that is almost always fatal once symptoms appear.
There are two primary types of rabies vaccines available:
1. Pre-exposure prophylaxis (PrEP) vaccines: These vaccines are given to individuals who are at high risk of coming into contact with the rabies virus, such as veterinarians, animal handlers, and travelers visiting areas where rabies is common. The vaccine series typically consists of three doses given over a period of 28 days.
2. Post-exposure prophylaxis (PEP) vaccines: These vaccines are administered to individuals who have already been exposed to the rabies virus, usually through a bite or scratch from an infected animal. The vaccine series typically consists of four doses given over a period of 14 days, along with a dose of rabies immune globulin (RIG) to provide immediate protection while the immune system responds to the vaccine.
Both types of rabies vaccines are highly effective at preventing the disease, but it is essential to receive them as soon as possible after exposure or before potential exposure, as the virus can be fatal if left untreated.
Population surveillance in a public health and medical context refers to the ongoing, systematic collection, analysis, interpretation, and dissemination of health-related data for a defined population over time. It aims to monitor the health status, identify emerging health threats or trends, and evaluate the impact of interventions within that population. This information is used to inform public health policy, prioritize healthcare resources, and guide disease prevention and control efforts. Population surveillance can involve various data sources, such as vital records, disease registries, surveys, and electronic health records.
Rotavirus vaccines are preventive measures used to protect against rotavirus infections, which are the leading cause of severe diarrhea and dehydration among infants and young children worldwide. These vaccines contain weakened or inactivated forms of the rotavirus, a pathogen that infects and causes symptoms by multiplying inside cells lining the small intestine.
The weakened or inactivated virus in the vaccine stimulates an immune response in the body, enabling it to recognize and fight off future rotavirus infections more effectively. The vaccines are usually administered orally, as a liquid droplet or on a sugar cube, to mimic natural infection through the gastrointestinal tract.
There are currently two licensed rotavirus vaccines available globally:
1. Rotarix (GlaxoSmithKline): This vaccine contains an attenuated (weakened) strain of human rotavirus and is given in a two-dose series, typically at 2 and 4 months of age.
2. RotaTeq (Merck): This vaccine contains five reassortant viruses, combining human and animal strains to provide broader protection. It is administered in a three-dose series, usually at 2, 4, and 6 months of age.
Rotavirus vaccines have been shown to significantly reduce the incidence of severe rotavirus gastroenteritis and related hospitalizations among infants and young children. The World Health Organization (WHO) recommends the inclusion of rotavirus vaccination in national immunization programs, particularly in countries with high child mortality rates due to diarrheal diseases.
Simian Virus 40 (SV40) is a polyomavirus that is found in both monkeys and humans. It is a DNA virus that has been extensively studied in laboratory settings due to its ability to transform cells and cause tumors in animals. In fact, SV40 was discovered as a contaminant of poliovirus vaccines that were prepared using rhesus monkey kidney cells in the 1950s and 1960s.
SV40 is not typically associated with human disease, but there has been some concern that exposure to the virus through contaminated vaccines or other means could increase the risk of certain types of cancer, such as mesothelioma and brain tumors. However, most studies have failed to find a consistent link between SV40 infection and cancer in humans.
The medical community generally agrees that SV40 is not a significant public health threat, but researchers continue to study the virus to better understand its biology and potential impact on human health.
The World Health Organization (WHO) is not a medical condition or term, but rather a specialized agency of the United Nations responsible for international public health. Here's a brief description:
The World Health Organization (WHO) is a specialized agency of the United Nations that acts as the global authority on public health issues. Established in 1948, WHO's primary role is to coordinate and collaborate with its member states to promote health, prevent diseases, and ensure universal access to healthcare services. WHO is headquartered in Geneva, Switzerland, and has regional offices around the world. It plays a crucial role in setting global health standards, monitoring disease outbreaks, and providing guidance on various public health concerns, including infectious diseases, non-communicable diseases, mental health, environmental health, and maternal, newborn, child, and adolescent health.
Cholera vaccines are preventive measures used to protect against the infection caused by the bacterium Vibrio cholerae. There are several types of cholera vaccines available, including:
1. Inactivated oral vaccine (ICCV): This vaccine contains killed whole-cell bacteria and is given in two doses, with each dose administered at least 14 days apart. It provides protection for up to six months and can be given to adults and children over the age of one year.
2. Live attenuated oral vaccine (LCV): This vaccine contains weakened live bacteria that are unable to cause disease but still stimulate an immune response. The most commonly used LCV is called CVD 103-HgR, which is given in a single dose and provides protection for up to three months. It can be given to adults and children over the age of six years.
3. Injectable cholera vaccine: This vaccine contains inactivated bacteria and is given as an injection. It is not widely available and its effectiveness is limited compared to oral vaccines.
Cholera vaccines are recommended for travelers visiting areas with known cholera outbreaks, particularly if they plan to eat food or drink water that may be contaminated. They can also be used in response to outbreaks to help control the spread of the disease. However, it is important to note that vaccination alone is not sufficient to prevent cholera infection and good hygiene practices, such as handwashing and safe food handling, should always be followed.
Seroepidemiologic studies are a type of epidemiological study that measures the presence and levels of antibodies in a population's blood serum to investigate the prevalence, distribution, and transmission of infectious diseases. These studies help to identify patterns of infection and immunity within a population, which can inform public health policies and interventions.
Seroepidemiologic studies typically involve collecting blood samples from a representative sample of individuals in a population and testing them for the presence of antibodies against specific pathogens. The results are then analyzed to estimate the prevalence of infection and immunity within the population, as well as any factors associated with increased or decreased risk of infection.
These studies can provide valuable insights into the spread of infectious diseases, including emerging and re-emerging infections, and help to monitor the effectiveness of vaccination programs. Additionally, seroepidemiologic studies can also be used to investigate the transmission dynamics of infectious agents, such as identifying sources of infection or tracking the spread of antibiotic resistance.
Typhoid-Paratyphoid vaccines are immunizations that protect against typhoid fever and paratyphoid fevers, which are caused by the Salmonella enterica serovars Typhi and Paratyphi, respectively. These vaccines contain inactivated or attenuated bacteria or specific antigens that stimulate an individual's immune system to develop immunity against these diseases without causing the illness itself. There are several types of typhoid-paratyphoid vaccines available, including:
1. Ty21a (oral live attenuated vaccine): This is a live but weakened form of the Salmonella Typhi bacteria. It is given orally in capsule form and requires a series of 4 doses taken every other day. The vaccine provides protection for about 5-7 years.
2. Vi polysaccharide (ViPS) typhoid vaccine: This vaccine contains purified Vi antigens from the Salmonella Typhi bacterium's outer capsular layer. It is given as an injection and provides protection for approximately 2-3 years.
3. Combined typhoid-paratyphoid A and B vaccines (Vi-rEPA): This vaccine combines Vi polysaccharide antigens from Salmonella Typhi and Paratyphi A and B. It is given as an injection and provides protection for about 3 years against typhoid fever and paratyphoid fevers A and B.
4. Typhoid conjugate vaccines (TCVs): These vaccines combine the Vi polysaccharide antigen from Salmonella Typhi with a protein carrier to enhance the immune response, particularly in children under 2 years of age. TCVs are given as an injection and provide long-lasting protection against typhoid fever.
It is important to note that none of these vaccines provides 100% protection, but they significantly reduce the risk of contracting typhoid or paratyphoid fevers. Additionally, good hygiene practices, such as handwashing and safe food handling, can further minimize the risk of infection.
Virus replication is the process by which a virus produces copies or reproduces itself inside a host cell. This involves several steps:
1. Attachment: The virus attaches to a specific receptor on the surface of the host cell.
2. Penetration: The viral genetic material enters the host cell, either by invagination of the cell membrane or endocytosis.
3. Uncoating: The viral genetic material is released from its protective coat (capsid) inside the host cell.
4. Replication: The viral genetic material uses the host cell's machinery to produce new viral components, such as proteins and nucleic acids.
5. Assembly: The newly synthesized viral components are assembled into new virus particles.
6. Release: The newly formed viruses are released from the host cell, often through lysis (breaking) of the cell membrane or by budding off the cell membrane.
The specific mechanisms and details of virus replication can vary depending on the type of virus. Some viruses, such as DNA viruses, use the host cell's DNA polymerase to replicate their genetic material, while others, such as RNA viruses, use their own RNA-dependent RNA polymerase or reverse transcriptase enzymes. Understanding the process of virus replication is important for developing antiviral therapies and vaccines.
Viral proteins are the proteins that are encoded by the viral genome and are essential for the viral life cycle. These proteins can be structural or non-structural and play various roles in the virus's replication, infection, and assembly process. Structural proteins make up the physical structure of the virus, including the capsid (the protein shell that surrounds the viral genome) and any envelope proteins (that may be present on enveloped viruses). Non-structural proteins are involved in the replication of the viral genome and modulation of the host cell environment to favor viral replication. Overall, a thorough understanding of viral proteins is crucial for developing antiviral therapies and vaccines.
Virus receptors are specific molecules (commonly proteins) on the surface of host cells that viruses bind to in order to enter and infect those cells. This interaction between the virus and its receptor is a critical step in the infection process. Different types of viruses have different receptor requirements, and identifying these receptors can provide important insights into the biology of the virus and potential targets for antiviral therapies.
An enterovirus is a type of virus that primarily infects the gastrointestinal tract. There are over 100 different types of enteroviruses, including polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses such as EV-D68 and EV-A71. These viruses are typically spread through close contact with an infected person, or by consuming food or water contaminated with the virus.
While many people infected with enteroviruses may not experience any symptoms, some may develop mild to severe illnesses such as hand, foot and mouth disease, herpangina, meningitis, encephalitis, myocarditis, and paralysis (in case of poliovirus). Infection can occur in people of all ages, but young children are more susceptible to infection and severe illness.
Prevention measures include practicing good hygiene, such as washing hands frequently with soap and water, avoiding close contact with sick individuals, and not sharing food or drinks with someone who is ill. There are also vaccines available to prevent poliovirus infection.
The Smallpox vaccine is not a live virus vaccine but is instead made from a vaccinia virus, which is a virus related to the variola virus (the virus that causes smallpox). The vaccinia virus used in the vaccine does not cause smallpox, but it does cause a milder illness with symptoms such as a fever and a rash of pustules or blisters at the site of inoculation.
The smallpox vaccine was first developed by Edward Jenner in 1796 and is one of the oldest vaccines still in use today. It has been highly effective in preventing smallpox, which was once a major cause of death and disability worldwide. In fact, smallpox was declared eradicated by the World Health Organization (WHO) in 1980, thanks in large part to the widespread use of the smallpox vaccine.
Despite the eradication of smallpox, the smallpox vaccine is still used today in certain circumstances. For example, it may be given to laboratory workers who handle the virus or to military personnel who may be at risk of exposure to the virus. The vaccine may also be used as an emergency measure in the event of a bioterrorism attack involving smallpox.
It is important to note that the smallpox vaccine is not without risks and can cause serious side effects, including a severe allergic reaction (anaphylaxis), encephalitis (inflammation of the brain), and myocarditis (inflammation of the heart muscle). As a result, it is only given to people who are at high risk of exposure to the virus and who have been determined to be good candidates for vaccination by a healthcare professional.
A tuberculosis vaccine, also known as the BCG (Bacillus Calmette-Guérin) vaccine, is a type of immunization used to prevent tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. The BCG vaccine contains a weakened strain of the bacteria that causes TB in cattle.
The BCG vaccine works by stimulating an immune response in the body, which helps to protect against severe forms of TB, such as TB meningitis and TB in children. However, it is not very effective at preventing pulmonary TB (TB that affects the lungs) in adults.
The BCG vaccine is not routinely recommended for use in the United States due to the low risk of TB infection in the general population. However, it may be given to people who are at high risk of exposure to TB, such as healthcare workers, laboratory personnel, and people traveling to countries with high rates of TB.
It is important to note that the BCG vaccine does not provide complete protection against TB and that other measures, such as testing and treatment for latent TB infection, are also important for controlling the spread of this disease.
The chickenpox vaccine, also known as varicella vaccine, is a preventive measure against the highly contagious viral infection caused by the varicella-zoster virus. The vaccine contains a live but weakened form of the virus, which stimulates the immune system to produce a response without causing the disease itself.
The chickenpox vaccine is typically given in two doses, with the first dose administered between 12 and 15 months of age and the second dose between 4 and 6 years of age. In some cases, the vaccine may be given to older children, adolescents, or adults who have not previously been vaccinated or who have never had chickenpox.
The chickenpox vaccine is highly effective at preventing severe cases of the disease and reducing the risk of complications such as bacterial infections, pneumonia, and encephalitis. It is also effective at preventing transmission of the virus to others.
Like any vaccine, the chickenpox vaccine can cause mild side effects such as soreness at the injection site, fever, or a mild rash. However, these side effects are generally mild and short-lived. Serious side effects are rare but may include allergic reactions or severe immune responses.
Overall, the chickenpox vaccine is a safe and effective way to prevent this common childhood disease and its potential complications.
I'm sorry for any confusion, but Poisson Distribution is actually a statistical concept rather than a medical term. Here's a general definition:
Poisson Distribution is a discrete probability distribution that expresses the probability of a given number of events occurring in a fixed interval of time or space, as long as these events occur with a known average rate and independently of each other. It is often used in fields such as physics, engineering, economics, and medical research to model rare events or low-probability phenomena.
In the context of medical research, Poisson Distribution might be used to analyze the number of adverse events that occur during a clinical trial, the frequency of disease outbreaks in a population, or the rate of successes or failures in a series of experiments.
A capsid is the protein shell that encloses and protects the genetic material of a virus. It is composed of multiple copies of one or more proteins that are arranged in a specific structure, which can vary in shape and symmetry depending on the type of virus. The capsid plays a crucial role in the viral life cycle, including protecting the viral genome from host cell defenses, mediating attachment to and entry into host cells, and assisting with the assembly of new virus particles during replication.
The Mumps Vaccine is a biological preparation intended to induce immunity against mumps, a contagious viral infection that primarily affects the salivary glands. The vaccine contains live attenuated (weakened) mumps virus, which stimulates the immune system to develop a protective response without causing the disease.
There are two types of mumps vaccines available:
1. The Jeryl Lynn strain is used in the United States and is part of the Measles, Mumps, and Rubella (MMR) vaccine and the Measles, Mumps, Rubella, and Varicella (MMRV) vaccine. This strain is derived from a clinical isolate obtained from the throat washings of a child with mumps in 1963.
2. The Urabe AM9 strain was used in some countries but has been discontinued in many places due to an increased risk of meningitis as a rare complication.
The MMR vaccine is typically given to children at 12-15 months of age and again at 4-6 years of age, providing long-lasting immunity against mumps in most individuals. The vaccine has significantly reduced the incidence of mumps and its complications worldwide.
I'm sorry for any confusion, but "United States" is a geopolitical entity, specifically the name of the country consisting of 50 states, and it is not a medical term or concept. Therefore, I can't provide a medical definition for it. If you have any questions related to health, medicine, or biology, I would be happy to try to help answer those!
Hepatitis A vaccines are inactivated or live attenuated viral vaccines that are administered to prevent infection and illness caused by the hepatitis A virus. The vaccine contains antigens that stimulate an immune response in the body, leading to the production of antibodies that protect against future infection with the virus.
The inactivated hepatitis A vaccine is made from viruses that have been chemically treated to destroy their ability to cause disease while preserving their ability to stimulate an immune response. This type of vaccine is typically given in two doses, six months apart, and provides long-term protection against the virus.
The live attenuated hepatitis A vaccine contains a weakened form of the virus that is unable to cause illness but can still stimulate an immune response. This type of vaccine is given as a single dose and provides protection against the virus for at least 20 years.
Hepatitis A vaccines are recommended for people who are at increased risk of infection, including travelers to areas where hepatitis A is common, men who have sex with men, people who use injection drugs, and people with chronic liver disease or clotting factor disorders. The vaccine is also recommended for children in certain states and communities where hepatitis A is endemic.
Immunologic adjuvants are substances that are added to a vaccine to enhance the body's immune response to the antigens contained in the vaccine. They work by stimulating the immune system and promoting the production of antibodies and activating immune cells, such as T-cells and macrophages, which help to provide a stronger and more sustained immune response to the vaccine.
Immunologic adjuvants can be derived from various sources, including bacteria, viruses, and chemicals. Some common examples include aluminum salts (alum), oil-in-water emulsions (such as MF59), and bacterial components (such as lipopolysaccharide or LPS).
The use of immunologic adjuvants in vaccines can help to improve the efficacy of the vaccine, particularly for vaccines that contain weak or poorly immunogenic antigens. They can also help to reduce the amount of antigen needed in a vaccine, which can be beneficial for vaccines that are difficult or expensive to produce.
It's important to note that while adjuvants can enhance the immune response to a vaccine, they can also increase the risk of adverse reactions, such as inflammation and pain at the injection site. Therefore, the use of immunologic adjuvants must be carefully balanced against their potential benefits and risks.
Immunization is defined medically as the process where an individual is made immune or resistant to an infectious disease, typically through the administration of a vaccine. The vaccine stimulates the body's own immune system to recognize and fight off the specific disease-causing organism, thereby preventing or reducing the severity of future infections with that organism.
Immunization can be achieved actively, where the person is given a vaccine to trigger an immune response, or passively, where antibodies are transferred to the person through immunoglobulin therapy. Immunizations are an important part of preventive healthcare and have been successful in controlling and eliminating many infectious diseases worldwide.
The Measles-Mumps-Rubella (MMR) vaccine is a combination immunization that protects against three infectious diseases: measles, mumps, and rubella. It contains live attenuated viruses of each disease, which stimulate an immune response in the body similar to that produced by natural infection but do not cause the diseases themselves.
The MMR vaccine is typically given in two doses, the first at 12-15 months of age and the second at 4-6 years of age. It is highly effective in preventing these diseases, with over 90% effectiveness reported after a single dose and near 100% effectiveness after the second dose.
Measles is a highly contagious viral disease that can cause fever, rash, cough, runny nose, and red, watery eyes. It can also lead to serious complications such as pneumonia, encephalitis (inflammation of the brain), and even death.
Mumps is a viral infection that primarily affects the salivary glands, causing swelling and tenderness in the cheeks and jaw. It can also cause fever, headache, muscle aches, and fatigue. Mumps can lead to serious complications such as deafness, meningitis (inflammation of the membranes surrounding the brain and spinal cord), and inflammation of the testicles or ovaries.
Rubella, also known as German measles, is a viral infection that typically causes a mild fever, rash, and swollen lymph nodes. However, if a pregnant woman becomes infected with rubella, it can cause serious birth defects such as hearing impairment, heart defects, and developmental delays in the fetus.
The MMR vaccine is an important tool in preventing these diseases and protecting public health.
In epidemiology, the incidence of a disease is defined as the number of new cases of that disease within a specific population over a certain period of time. It is typically expressed as a rate, with the number of new cases in the numerator and the size of the population at risk in the denominator. Incidence provides information about the risk of developing a disease during a given time period and can be used to compare disease rates between different populations or to monitor trends in disease occurrence over time.
Viral DNA refers to the genetic material present in viruses that consist of DNA as their core component. Deoxyribonucleic acid (DNA) is one of the two types of nucleic acids that are responsible for storing and transmitting genetic information in living organisms. Viruses are infectious agents much smaller than bacteria that can only replicate inside the cells of other organisms, called hosts.
Viral DNA can be double-stranded (dsDNA) or single-stranded (ssDNA), depending on the type of virus. Double-stranded DNA viruses have a genome made up of two complementary strands of DNA, while single-stranded DNA viruses contain only one strand of DNA.
Examples of dsDNA viruses include Adenoviruses, Herpesviruses, and Poxviruses, while ssDNA viruses include Parvoviruses and Circoviruses. Viral DNA plays a crucial role in the replication cycle of the virus, encoding for various proteins necessary for its multiplication and survival within the host cell.
I'm sorry for any confusion, but "India" is not a medical term or concept. It is a country in South Asia, the second-most populous country in the world, known for its rich history, diverse culture, and numerous contributions to various fields including medicine. If you have any questions related to medical topics, I would be happy to help answer them!
Streptococcal vaccines are immunizations designed to protect against infections caused by Streptococcus bacteria. These vaccines contain antigens, which are substances that trigger an immune response and help the body recognize and fight off specific types of Streptococcus bacteria. There are several different types of streptococcal vaccines available or in development, including:
1. Pneumococcal conjugate vaccine (PCV): This vaccine protects against Streptococcus pneumoniae, a type of bacteria that can cause pneumonia, meningitis, and other serious infections. PCV is recommended for all children under 2 years old, as well as older children and adults with certain medical conditions.
2. Pneumococcal polysaccharide vaccine (PPSV): This vaccine also protects against Streptococcus pneumoniae, but it is recommended for adults 65 and older, as well as younger people with certain medical conditions.
3. Streptococcus pyogenes vaccine: This vaccine is being developed to protect against Group A Streptococcus (GAS), which can cause a variety of infections, including strep throat, skin infections, and serious diseases like rheumatic fever and toxic shock syndrome. There are several different GAS vaccine candidates in various stages of development.
4. Streptococcus agalactiae vaccine: This vaccine is being developed to protect against Group B Streptococcus (GBS), which can cause serious infections in newborns, pregnant women, and older adults with certain medical conditions. There are several different GBS vaccine candidates in various stages of development.
Overall, streptococcal vaccines play an important role in preventing bacterial infections and reducing the burden of disease caused by Streptococcus bacteria.
Anthrax vaccines are biological preparations designed to protect against anthrax, a potentially fatal infectious disease caused by the bacterium Bacillus anthracis. Anthrax can affect both humans and animals, and it is primarily transmitted through contact with contaminated animal products or, less commonly, through inhalation of spores.
There are two types of anthrax vaccines currently available:
1. Anthrax Vaccine Adsorbed (AVA): This vaccine is licensed for use in the United States and is approved for pre-exposure prophylaxis in high-risk individuals, such as military personnel and laboratory workers who handle the bacterium. AVA contains a cell-free filtrate of cultured B. anthracis cells that have been chemically treated to render them non-infectious. The vaccine works by stimulating the production of antibodies against protective antigens (PA) present in the bacterial culture.
2. Recombinant Anthrax Vaccine (rPA): This vaccine, also known as BioThrax, is a newer generation anthrax vaccine that was approved for use in the United States in 2015. It contains only the recombinant protective antigen (rPA) of B. anthracis, which is produced using genetic engineering techniques. The rPA vaccine has been shown to be as effective as AVA in generating an immune response and offers several advantages, including a more straightforward manufacturing process, fewer side effects, and a longer shelf life.
Both vaccines require multiple doses for initial immunization, followed by periodic booster shots to maintain protection. Anthrax vaccines are generally safe and effective at preventing anthrax infection; however, they may cause mild to moderate side effects, such as soreness at the injection site, fatigue, and muscle aches. Severe allergic reactions are rare but possible.
It is important to note that anthrax vaccines do not provide immediate protection against anthrax infection. They require several weeks to stimulate an immune response, so they should be administered before potential exposure to the bacterium. In cases of known or suspected exposure to anthrax, antibiotics are used as a primary means of preventing and treating the disease.
Dengue vaccines are designed to protect against dengue fever, a mosquito-borne viral disease that can cause severe flu-like symptoms and potentially life-threatening complications. Dengue is caused by four distinct serotypes of the virus (DENV-1, DENV-2, DENV-3, and DENV-4), and infection with one serotype does not provide immunity against the others.
The first licensed dengue vaccine, Dengvaxia (CYD-TDV), is a chimeric yellow fever-dengue tetravalent vaccine developed by Sanofi Pasteur. It is approved for use in several countries and has demonstrated efficacy against dengue fever caused by all four serotypes in clinical trials. However, the vaccine has raised concerns about the risk of severe disease in individuals who have not been previously exposed to dengue. As a result, it is recommended primarily for people with a documented past dengue infection or living in areas with high dengue prevalence and where the benefits outweigh the risks.
Another dengue vaccine candidate, Takeda's TAK-003 (also known as TDV), is a live attenuated tetravalent dengue vaccine that has shown efficacy against all four serotypes in clinical trials. It was granted approval by the European Medicines Agency (EMA) and several other countries for use in individuals aged 4-16 years old, living in endemic areas.
Research and development of additional dengue vaccine candidates are ongoing to address concerns about safety, efficacy, and accessibility, particularly for at-risk populations in low- and middle-income countries where dengue is most prevalent.
Enterovirus B, Human (HEVB) is a type of enterovirus that infects humans. Enteroviruses are small viruses that belong to the Picornaviridae family and are named after the Greek word "pico" meaning small. They are further classified into several species, including Human Enterovirus B (HEV-B).
HEVB includes several serotypes, such as Coxsackievirus A9, A16, and B types, and Echoviruses. These viruses are typically transmitted through the fecal-oral route or respiratory droplets and can cause a range of illnesses, from mild symptoms like fever, rash, and sore throat to more severe diseases such as meningitis, myocarditis, and paralysis.
HEVB infections are common worldwide, and people of all ages can be affected. However, young children and individuals with weakened immune systems are at higher risk for severe illness. Prevention measures include good hygiene practices, such as washing hands frequently and avoiding close contact with sick individuals. There is no specific treatment for HEVB infections, and most cases resolve on their own within a few days to a week. However, hospitalization may be necessary for severe cases.
Virosomes are artificially constructed spherical vesicles composed of lipids and viral envelope proteins. They are used as a delivery system for vaccines and other therapeutic agents. In the context of vaccines, virosomes can be used to present viral antigens to the immune system in a way that mimics a natural infection, thereby inducing a strong immune response.
Virosome-based vaccines have several advantages over traditional vaccines. For example, they are non-infectious, meaning they do not contain live or attenuated viruses, which makes them safer for certain populations such as immunocompromised individuals. Additionally, virosomes can be engineered to target specific cells in the body, leading to more efficient uptake and presentation of antigens to the immune system.
Virosome-based vaccines have been developed for a variety of diseases, including influenza, hepatitis A, and HIV. While they are not yet widely used, they show promise as a safe and effective alternative to traditional vaccine approaches.
Bacterial antibodies are a type of antibodies produced by the immune system in response to an infection caused by bacteria. These antibodies are proteins that recognize and bind to specific antigens on the surface of the bacterial cells, marking them for destruction by other immune cells. Bacterial antibodies can be classified into several types based on their structure and function, including IgG, IgM, IgA, and IgE. They play a crucial role in the body's defense against bacterial infections and provide immunity to future infections with the same bacteria.
Cysteine endopeptidases are a type of enzymes that cleave peptide bonds within proteins. They are also known as cysteine proteases or cysteine proteinases. These enzymes contain a catalytic triad consisting of three amino acids: cysteine, histidine, and aspartate. The thiol group (-SH) of the cysteine residue acts as a nucleophile and attacks the carbonyl carbon of the peptide bond, leading to its cleavage.
Cysteine endopeptidases play important roles in various biological processes, including protein degradation, cell signaling, and inflammation. They are involved in many physiological and pathological conditions, such as apoptosis, immune response, and cancer. Some examples of cysteine endopeptidases include cathepsins, caspases, and calpains.
It is important to note that these enzymes require a reducing environment to maintain the reduced state of their active site cysteine residue. Therefore, they are sensitive to oxidizing agents and inhibitors that target the thiol group. Understanding the structure and function of cysteine endopeptidases is crucial for developing therapeutic strategies that target these enzymes in various diseases.
Viral hepatitis vaccines are vaccines that prevent infection caused by various hepatitis viruses, including hepatitis A and B. These vaccines contain antigens that stimulate the immune system to produce antibodies that protect against infection with the corresponding virus. The vaccines are typically administered through injection and may require multiple doses for full protection.
The hepatitis A vaccine is made from inactivated hepatitis A virus, while the hepatitis B vaccine is made from recombinant hepatitis B surface antigen. Both vaccines have been shown to be highly effective in preventing infection and reducing the risk of complications associated with viral hepatitis, such as liver disease and liver cancer.
It's important to note that there are no vaccines available for other types of viral hepatitis, such as hepatitis C, D, or E. Prevention strategies for these types of viral hepatitis typically involve measures to reduce exposure to the virus, such as safe injection practices and avoiding high-risk behaviors like sharing needles or having unprotected sex with infected individuals.
The Yellow Fever Vaccine is a vaccine that protects against the yellow fever virus, which is transmitted to humans through the bites of infected mosquitoes. The vaccine contains live, weakened yellow fever virus, and it works by stimulating the immune system to produce an immune response that provides protection against the disease.
The yellow fever vaccine is recommended for people who are traveling to areas where yellow fever is common, including parts of Africa and South America. It is also required for entry into some countries in these regions. The vaccine is generally safe and effective, but it can cause mild side effects such as headache, muscle pain, and fever in some people. Serious side effects are rare, but may include allergic reactions or infection with the weakened virus used in the vaccine.
It's important to note that yellow fever vaccine may not be recommended for certain individuals, including infants younger than 6 months, pregnant women, people with weakened immune systems, and those with a history of severe allergic reaction to a previous dose of the vaccine or any component of the vaccine. It is always best to consult with a healthcare provider before receiving any vaccination.
A plague vaccine is a type of immunization used to protect against the bacterial infection caused by Yersinia pestis, the causative agent of plague. The vaccine contains killed or weakened forms of the bacteria, which stimulate the immune system to produce antibodies and activate immune cells that can recognize and fight off the infection if the person is exposed to the bacteria in the future.
There are several types of plague vaccines available, including whole-cell killed vaccines, live attenuated vaccines, and subunit vaccines. The choice of vaccine depends on various factors, such as the target population, the route of exposure (e.g., respiratory or cutaneous), and the desired duration of immunity.
Plague vaccines have been used for many years to protect military personnel and individuals at high risk of exposure to plague, such as laboratory workers and people living in areas where plague is endemic. However, their use is not widespread, and they are not currently recommended for general use in the United States or other developed countries.
It's important to note that while plague vaccines can provide some protection against the disease, they are not 100% effective, and other measures such as antibiotics and insect control are also important for preventing and treating plague infections.
A fungal vaccine is a biological preparation that provides active acquired immunity against fungal infections. It contains one or more fungal antigens, which are substances that can stimulate an immune response, along with adjuvants to enhance the immune response. The goal of fungal vaccines is to protect against invasive fungal diseases, especially in individuals with weakened immune systems, such as those undergoing chemotherapy, organ transplantation, or HIV/AIDS treatment.
Fungal vaccines can work by inducing both humoral and cell-mediated immunity. Humoral immunity involves the production of antibodies that recognize and neutralize fungal antigens, while cell-mediated immunity involves the activation of T cells to directly attack infected cells.
Currently, there are no licensed fungal vaccines available for human use, although several candidates are in various stages of development and clinical trials. Some examples include vaccines against Candida albicans, Aspergillus fumigatus, Cryptococcus neoformans, and Pneumocystis jirovecii.
Polymerase Chain Reaction (PCR) is a laboratory technique used to amplify specific regions of DNA. It enables the production of thousands to millions of copies of a particular DNA sequence in a rapid and efficient manner, making it an essential tool in various fields such as molecular biology, medical diagnostics, forensic science, and research.
The PCR process involves repeated cycles of heating and cooling to separate the DNA strands, allow primers (short sequences of single-stranded DNA) to attach to the target regions, and extend these primers using an enzyme called Taq polymerase, resulting in the exponential amplification of the desired DNA segment.
In a medical context, PCR is often used for detecting and quantifying specific pathogens (viruses, bacteria, fungi, or parasites) in clinical samples, identifying genetic mutations or polymorphisms associated with diseases, monitoring disease progression, and evaluating treatment effectiveness.
Protein biosynthesis is the process by which cells generate new proteins. It involves two major steps: transcription and translation. Transcription is the process of creating a complementary RNA copy of a sequence of DNA. This RNA copy, or messenger RNA (mRNA), carries the genetic information to the site of protein synthesis, the ribosome. During translation, the mRNA is read by transfer RNA (tRNA) molecules, which bring specific amino acids to the ribosome based on the sequence of nucleotides in the mRNA. The ribosome then links these amino acids together in the correct order to form a polypeptide chain, which may then fold into a functional protein. Protein biosynthesis is essential for the growth and maintenance of all living organisms.
RNA-dependent RNA polymerase, also known as RNA replicase, is an enzyme that catalyzes the production of RNA from an RNA template. It plays a crucial role in the replication of certain viruses, such as positive-strand RNA viruses and retroviruses, which use RNA as their genetic material. The enzyme uses the existing RNA strand as a template to create a new complementary RNA strand, effectively replicating the viral genome. This process is essential for the propagation of these viruses within host cells and is a target for antiviral therapies.
BALB/c is an inbred strain of laboratory mouse that is widely used in biomedical research. The strain was developed at the Institute of Cancer Research in London by Henry Baldwin and his colleagues in the 1920s, and it has since become one of the most commonly used inbred strains in the world.
BALB/c mice are characterized by their black coat color, which is determined by a recessive allele at the tyrosinase locus. They are also known for their docile and friendly temperament, making them easy to handle and work with in the laboratory.
One of the key features of BALB/c mice that makes them useful for research is their susceptibility to certain types of tumors and immune responses. For example, they are highly susceptible to developing mammary tumors, which can be induced by chemical carcinogens or viral infection. They also have a strong Th2-biased immune response, which makes them useful models for studying allergic diseases and asthma.
BALB/c mice are also commonly used in studies of genetics, neuroscience, behavior, and infectious diseases. Because they are an inbred strain, they have a uniform genetic background, which makes it easier to control for genetic factors in experiments. Additionally, because they have been bred in the laboratory for many generations, they are highly standardized and reproducible, making them ideal subjects for scientific research.
Polio eradication
Herdis von Magnus
MECACAR
Closed community
Polio
Albert Sabin
Healthcare in Cuba
Viral quasispecies
Tatsuji Nomura
Non-specific effect of vaccines
Poliovirus
Vaccine
Deuterium
Yvonne Maldonado
Demographics of the Gambia
Demographics of Sierra Leone
Demographics of Djibouti
Demographics of Mozambique
Demographics of Guinea-Bissau
Demographics of Ethiopia
Demographics of Liberia
Demographics of Mauritania
Demographics of Chad
Demographics of the Republic of the Congo
Demographics of Senegal
Demographics of Malawi
Demographics of Madagascar
Demographics of Nigeria
Demographics of Niger
Demographics of Guinea
Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016 | MMWR
From trivalent to bivalent oral poliovirus vaccine | Virology Blog
Oral poliovirus vaccine
Dermatologic Manifestations of Gianotti-Crosti Syndrome: Background, Pathophysiology, Etiology of Gianotti-Crosti Syndrome
Table 1 - Emergence of Vaccine-Derived Polioviruses during Ebola Virus Disease Outbreak, Guinea, 2014-2015 - Volume 24, Number...
Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of...
Emergence of vaccine-derived poliovirus type 2 after using monovalent type 2 oral poliovirus vaccine in an outbreak response,...
Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2020-June 2021 | MMWR
Poliomyelitis Prevention in the United States
Advanced Search Results - Public Health Image Library(PHIL)
Polio vaccine - what you need to know: MedlinePlus Medical Encyclopedia
for Inmazeb, Ebola monoclonal antibodies (atoltivimab/maftivimab/odesivimab) dosing, indications, interactions, adverse effects...
E003: Refrigerators and Freezers | WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization...
Viral infection - Latest research and news | Nature
GMO Regulatory Aspects of Novel Investigational Vaccine Candidates | IntechOpen
Tutorial in biostatistics: the self-controlled case series method
A Look at Each Vaccine: Polio Vaccine | Children's Hospital of Philadelphia
Quantity of Vaccine Poliovirus Shed Determines the Titer of the Serum Neutralizing Antibody Response in Indian Children Who...
Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral...
The effect of azithromycin on the immunogenicity of oral poliovirus vaccine: a double-blind randomised placebo-controlled trial...
The effect of azithromycin on the immunogenicity of oral poliovirus vaccine: a double-blind randomised placebo-controlled trial...
Polio eradication - Wikipedia
Part 1, Chapter 12: Manual Appendix VI | Part 1
condition
Circulating vaccine-derived poliovirus - GPEI
Food and Drug Regulations
Circulating vaccine-derived polioviruses5
- To address the risks posed by type 2 circulating vaccine-derived polioviruses, which have caused hundreds of paralytic poliomyelitis cases since 2006, the type 2 component of oral poliovirus vaccine was scheduled for global withdrawal through a synchronized switch from trivalent oral poliovirus vaccine (tOPV) to bivalent oral poliovirus vaccine (bOPV). (cdc.gov)
- To prevent further cases of poliomyelitis caused by circulating vaccine-derived polioviruses, WHO planned a synchronized, global switch from trivalent OPV to bivalent OPV on 17 April 2016. (virology.ws)
- Circulating vaccine-derived polioviruses (cVDPVs) can emerge in settings with low poliovirus population immunity and cause paralysis. (cdc.gov)
- Recent polio outbreaks in both endemic and non-endemic countries stem from poliovirus strains originally contained in OPV, called circulating vaccine-derived polioviruses (cVDPV) . (asm.org)
- With polio cases caused by wild poliovirus type 1 and circulating vaccine-derived polioviruses of all three types (1, 2 and 3) reported in 2022, the number, formulation, and use of poliovirus vaccines poses challenges for national immunization programs and vaccine suppliers. (cdc.gov)
Poliomyelitis38
- Since the 1988 World Health Assembly resolution to eradicate poliomyelitis, transmission of the three types of wild poliovirus (WPV) has been sharply reduced ( 1 ). (cdc.gov)
- Consequently a small number of recipients, and their contacts, contract poliomyelitis from the vaccine. (virology.ws)
- These revised recommendations of the Advisory Committee on Immunization Practices (ACIP) replace recommendations on poliomyelitis issued in 1982 and 1987, and present a new ACIP poliovirus vaccination policy that increases reliance on inactivated poliovirus vaccine (IPV). (cdc.gov)
- In particular, the relative benefits of OPV to the U.S. population have diminished because of the elimination of wild-virus-associated poliomyelitis in the Western Hemisphere and the reduced threat of poliovirus importation into the United States. (cdc.gov)
- The risk for vaccine-associated poliomyelitis caused by OPV is now judged less acceptable because of the diminished risk for wild-virus-associated disease (indigenous or imported). (cdc.gov)
- Implementation of these recommendations should reduce the risk for vaccine-associated paralytic poliomyelitis and facilitate a transition to exclusive use of IPV following further progress in global polio eradication. (cdc.gov)
- Since the introduction of poliovirus vaccines in the 1950s and 1960s, poliomyelitis control has been achieved in the United States, the Americas, and elsewhere (1,2). (cdc.gov)
- In the United States, the last indigenously acquired cases of poliomyelitis caused by wild poliovirus were detected in 1979 (3). (cdc.gov)
- In 1985, the countries of the Americas established a goal of regional elimination of wild poliovirus by the year 1990 (4), and in 1988, the World Health Assembly adopted the goal of global poliomyelitis eradication by the year 2000 (5). (cdc.gov)
- In the Americas, the last case of poliomyelitis associated with isolation of wild poliovirus was detected in Peru in 1991 (6). (cdc.gov)
- The United States can remain free of poliomyelitis only by reducing or eliminating the risk for poliovirus importation. (cdc.gov)
- Vaccine-associated paralytic poliomyelitis (VAPP) has been the only indigenous form of the disease in the United States since 1979. (cdc.gov)
- Polio (or poliomyelitis) is a disabling and life-threatening disease caused by poliovirus, which can infect a person's spinal cord, leading to paralysis. (medlineplus.gov)
- Replication of oral poliovirus vaccine (OPV) in the intestine (ie, vaccine take) is associated with seroconversion and protection against poliomyelitis. (liverpool.ac.uk)
- Polio eradication, the permanent global cessation of circulation of the poliovirus and hence elimination of the poliomyelitis (polio) it causes, is the aim of a multinational public health effort begun in 1988, led by the World Health Organization (WHO), the United Nations Children's Fund (UNICEF) and the Rotary Foundation. (wikipedia.org)
- C.04.122 Poliomyelitis vaccine shall be an aqueous suspension of killed poliomyelitis viruses, Types I, II, and III. (gc.ca)
- C.04.123 Poliomyelitis vaccine shall be prepared in acceptable tissue culture medium from strains of poliomyelitis virus proven capable of producing vaccine of acceptable potency. (gc.ca)
- C.04.124 Poliomyelitis vaccine in its final form shall contain not more than 0.35 milligram per millilitre of total nitrogen, nor more than one part per million of animal serum. (gc.ca)
- C.04.125 No person shall sell poliomyelitis vaccine unless it has been tested by an acceptable method for potency and safety and when so tested it shall be safe and of acceptable potency. (gc.ca)
- C.04.127 The expiration date of the poliomyelitis vaccine shall be not later than 12 months after the date of the last satisfactory potency test unless evidence, satisfactory to the Minister, is presented that a longer period is appropriate. (gc.ca)
- this patient developed paralytic poliomyelitis 7 years after the last administration of trivalent oral poliovirus vaccine. (medscape.com)
- Polio vaccines are vaccines used to prevent poliomyelitis (polio). (wikipedia.org)
- [2] Oral polio vaccines cause about three cases of vaccine-associated paralytic poliomyelitis per million doses given. (wikipedia.org)
- [2] However, the emergence of circulating vaccine-derived poliovirus (cVDPV), a form of the vaccine virus that has reverted to causing poliomyelitis, has led to the development of novel oral polio vaccine type 2 (nOPV2) which aims to make the vaccine safer and thus stop further outbreaks of cVDPV2. (wikipedia.org)
- This suggests that using attenuated Sabin strains to prepare inactivated poliovirus vaccines, such as sIPV, could be a viable option for preventing poliomyelitis. (expresshealthcaremgmt.com)
- Recommendations to assure the quality, safety and efficacy of live attenuated poliomyelitis vaccine (oral). (who.int)
- Vaccine- associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. (who.int)
- Vaccine- associated paralytic poliomyelitis (VAPP) is a rare adverse event associated with oral poliovirus vaccine (OPV). (who.int)
- Polio, or poliomyelitis , is a disabling and life-threatening disease caused by the poliovirus. (unfoundation.org)
- Since the advent of the Global Polio Eradication Initiative in 1988, the incidence of poliomyelitis due to wild-type poliovirus has declined from an estimated 350,000 cases in 1988 to 416 reported cases in 2013. (stanford.edu)
- The Salk vaccine is composed of killed poliomyelitis virus. (scienceclarified.com)
- The Sabin vaccine is composed of live (but weakened and harmless) poliomyelitis virus. (scienceclarified.com)
- Both vaccines are effective against all forms of the poliomyelitis virus. (scienceclarified.com)
- According to ACIP, an all-IPV schedule is needed to eliminate the risk of vaccine-associated paralytic poliomyelitis while maintaining population immunity. (aafp.org)
- In addition to background information that led to the recommendation for an all-IPV schedule, the ACIP report includes data on the epidemiology of poliomyelitis and of vaccination coverage, as well as information on vaccine-associated paralytic poliomyelitis. (aafp.org)
- According to ACIP, cases of vaccine-associated paralytic poliomyelitis occurred almost immediately after introduction of the live attenuated poliovirus vaccine. (aafp.org)
- The overall risk of vaccine-associated paralytic poliomyelitis is estimated to be one case in 2.4 million doses of OPV distributed. (aafp.org)
- The ACIP report states that adoption of an all-IPV schedule for childhood polio vaccination is intended to eliminate the risk of vaccine-associated paralytic poliomyelitis. (aafp.org)
Vaccination24
- However, attenuated polioviruses in OPV can undergo genetic changes during replication, and in communities with low vaccination coverage, can result in vaccine-derived polioviruses (VDPVs) that can cause paralytic polio indistinguishable from the disease caused by WPVs ( 2 ). (cdc.gov)
- The revised recommendations include three options for poliovirus vaccination, all of which meet acceptable standards of care: sequential vaccination with IPV followed by OPV, OPV alone, or IPV alone. (cdc.gov)
- Refer to vaccine guidelines for vaccination timing during and following treatment. (medscape.com)
- Here the authors evaluate neutralizing antibodies following COVID-19 bivalent vaccination and find that both Pfizer BA.5 (BNT162b2) and Moderna BA.1 (mRNA-1273) vaccines elicit similar neutralization against Omicron subvariants BA.1, BA.5, BQ.1.1, and XBB.1.5 in patients with end-stage kidney disease. (nature.com)
- A primary vaccination series with either vaccine produces immunity to all three types of poliovirus in more than 95 percent of recipients. (ihs.gov)
- discuss the history of polio globally and the United States, outline the current investigation and response to the case of paralytic polio New York, describe how to recognize, diagnose, and report suspected paralytic polio cases in the United States, and distinguish the differences between inactivated polio vaccine and oral polio vaccine and the importance of maintaining high polio vaccination coverage. (cdc.gov)
- understand the history of polio in the U.S. and globally, describe polioviruses, understand the incubation period and transmission of poliovirus, and understand the impact of polio vaccination and the different types of vaccine. (cdc.gov)
- Interruption of person-to-person transmission of the virus by vaccination is important in global polio eradication , [15] since no long-term carrier state exists for poliovirus in individuals with normal immune function, polio viruses have no non-primate reservoir in nature, [16] and survival of the virus in the environment for an extended period of time appears to be remote. (wikipedia.org)
- Oral polio vaccines were easier to administer than IPV, as it eliminated the need for sterile syringes and therefore was more suitable for mass vaccination campaigns. (wikipedia.org)
- Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: Poliovirus vaccination. (who.int)
- Footnote 2 The European Rotavirus Vaccination Advocacy Committee ( ERVAC ) has recently advocated introduction of rotavirus vaccine into childhood immunization programs, although the members agree that further studies on the burden of rotavirus gastroenteritis in Europe need to be done for a better evaluation of the cost and benefit of rotavirus vaccination programs. (canada.ca)
- The routine childhood vaccination regimen in the U.S. consists of 4 doses of an inactivated polio vaccine… three doses are considered 99 to 100% effective against paralytic polio ," she adds. (yahoo.com)
- A nurse gives twins the oral polio vaccine as part of the Palestinian Ministry of Health's vaccination campaign. (unfoundation.org)
- 6 GPEI estimates that in the same period, without vaccination with OPV, more than 6.5 million children would have been paralysed by wild poliovirus. (bmj.com)
- Since then, substantial progress has been made in vaccination and surveillance and, by the end of the year, 19 of the 23 EMR countries are expected to have interrupted poliovirus transmission. (cdc.gov)
- Iran and Tunisia conducted targeted subnational campaigns in provinces at risk for poliovirus importation and/or with suboptimal vaccination coverage, and NIDs have not been considered necessary in Cyprus. (cdc.gov)
- To further the control of disease by vaccination, we must develop safe and effective new vaccines to combat infectious diseases, and address the public's concerns. (nature.com)
- Effectiveness of oral rotavirus vaccination in England against rotavirus-confirmed and all-cause acute gastroenteritis. (lshtm.ac.uk)
- Poliovirus appears to be spreading where I live in London-so I took the first chance I had to get my toddler a booster vaccination. (technologyreview.com)
- That's why many countries have switched to injected polio vaccines-the UK moved away from oral polio vaccination in 2004, for example. (technologyreview.com)
- The $3.6 million dollar grant will allow Maldonado and her lab group to study the impact of oral polio vaccination rates on the virus's circulation in Mexican communities, the results of which may inform public policy decision making in that country, as well as globally. (stanford.edu)
- Importantly, it is better for babies to receive multiple vaccines at the same time than to space the injections out because the latter prolongs the time it takes for adequate vaccination, increases the risk of infection before the baby is adequately protected, and increases the number of visits for vaccine appointments," Dr Rowe-Porter said. (jamaica-gleaner.com)
- A significantly higher salivary SlgA antibody response was obtained in breastfed than in nonbreastfed Italian infants after parenteral vaccination with diphtheria and tetanus toxoids and after oral poliovirus vaccination [2]. (unu.edu)
- Data from the National Immunization Survey show that vaccination coverage with at least three doses of poliovirus vaccine in children from 29 to 35 months of age increased from 88 percent in 1995 to 92 percent in 1996. (aafp.org)
CVDPV9
- In response to an outbreak of circulating vaccine-derived poliovirus (cVDPV) type 2 in the Philippines in 2019-2020, several rounds of supplementary immunization activities using the monovalent type 2 oral poliovirus vaccine (OPV) were conducted for the first time in the Western Pacific Region. (who.int)
- To prevent the emergence and further spread of cVDPV type 2, several interventions could be implemented including optimizing outbreak responses by using the monovalent type 2 OPV, accelerating the availability of the novel type 2 OPV, strengthening routine immunization using inactivated polio vaccine and eventually replacing OPV with inactivated poliovirus vaccine for routine immunization. (who.int)
- Circulating vaccine-derived poliovirus (cVDPV) outbreaks* occur when transmission of Sabin strain poliovirus is prolonged in underimmunized populations, allowing viral genetic reversion to neurovirulence, resulting in cases of paralytic polio ( 1 - 3 ). (cdc.gov)
- Several countries5 in the African Region experienced circulating vaccine-derived poliovirus (cVDPV) outbreaks and isolated VDPVs in 2015. (who.int)
- Recent polio cases arise from two sources, the original 'wild' poliovirus (WPV), and the much more prevalent mutated oral vaccine strains, known as circulating vaccine-derived poliovirus (cVDPV). (wikipedia.org)
- Vaccines against each of the three wild strains of polio have given rise to strains of cVDPV, with cVDPV2 being most prominent. (wikipedia.org)
- However, on rare occasions, in under-immunized populations, the live attenuated virus originally contained in OPV can mutate into circulating vac- cine-derived poliovirus (cVDPV). (who.int)
- Unfortunately, cVDPV strains 'are a major challenge to accomplishing this goal,' as they promote community spread of poliovirus, which can only be combatted with OPV, thus perpetuating the cycle. (asm.org)
- Of the 3 types of cVDPV, type 2 strains (cVDPV2) are responsible for over 90% of vaccine-associated outbreaks worldwide . (asm.org)
Immunity20
- After oral administration of poliovirus vaccine, the virus replicates in the intestine, conferring immunity to subsequent infection. (virology.ws)
- Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. (bvsalud.org)
- The relative immunity induced by sequential administration of inactivated poliovirus vaccine (IPV) produced in human diploid cells and live attenuated oral poliovirus vaccine (OPV) was evaluated by randomization of 510 infants to receive IPV and OPV sequentially according to one of three experimental schedules, IPV only, or OPV only. (johnshopkins.edu)
- however, epidemics could occur if the high immunity level of the general population is not maintained by immunizing children routinely or If wild poliovirus is introduced into susceptible populations in communities with low immunization levels. (ihs.gov)
- In the United States inapparent Infection with wild poliovirus strains no longer contributes significantly to establishing or maintaining immunity. (ihs.gov)
- OPV also provided longer-lasting immunity than the Salk vaccine, as it provides both humoral immunity and cell-mediated immunity . (wikipedia.org)
- One dose of OPV produces immunity to all three poliovirus serotypes in roughly 50% of recipients. (wikipedia.org)
- OPV produces excellent immunity in the intestine , the primary site of wild poliovirus entry, which helps prevent infection with wild virus in areas where the virus is endemic . (wikipedia.org)
- As with other live-virus vaccines, immunity initiated by OPV is probably lifelong. (wikipedia.org)
- The study aimed to determine the duration of immunity conferred by sIPV and its potential as an alternative to oral poliovirus vaccine (OPV). (expresshealthcaremgmt.com)
- These findings are particularly significant for developing nations in the postpolio era, as vaccines with long-lasting immunity are crucial for polio eradication efforts. (expresshealthcaremgmt.com)
- New combination vaccines should induce similar or superior levels of neutralizing antibody in serum for individual protection against paralytic disease and mucosal immunity that effectively decreases viral replication in the intestine and pharynx for population protection against transmission of poliovirus. (who.int)
- Perhaps the surest way of guaranteeing immunity - and of ultimately eradicating polio - is to first immunize with an injection of the inactive virus and then follow with the oral vaccine as a booster. (latimes.com)
- The oral vaccine contains a weakened form of the poliovirus that induces immunity. (unfoundation.org)
- Advances in our understanding of the determinants of protective immunity and immunological memory, of the mechanisms by which adjuvants affect the quality and magnitude of immunological responses, and of microbial genomics, offer the promise for new and more effective vaccines in the near future. (nature.com)
- BACKGROUND: To inform response strategies, we examined type 1 humoral and intestinal immunity induced by 1) one fractional inactivated poliovirus vaccine (fIPV) dose given with monovalent oral poliovirus vaccine (mOPV1), and 2) mOPV1 versus bivalent OPV (bOPV). (cdc.gov)
- According to Dr Julia Rowe-Porter, acting director at the Family Health Unit, Health Services Planning and Integration Branch at the Ministry of Health and Wellness (MOHW), vaccines are harmless substances, usually given by injection, that help your body to develop immunity to harmful germs before you get exposed to them. (jamaica-gleaner.com)
- In the late 1950s, Russian-born American virologist Albert Sabin (1906-1993) developed a vaccine that has proven to provide longer immunity against the disease than the Salk vaccine. (scienceclarified.com)
- The vaccine goes straight to the intestinal tract and builds up immunity there as well as in other parts of the body. (scienceclarified.com)
- Vaccine antigens bio-encapsulated in plant cells upon oral delivery after priming, conferred both mucosal and systemic immunity and protection against bacterial, viral or protozoan pathogens or toxin challenge. (upenn.edu)
Outbreaks13
- All countries not already using inactivated polio vaccine (IPV) have committed to introducing it as part of their efforts to reduce risks associated with potential type 2 polio outbreaks after the switch. (cdc.gov)
- Complementing the switch from tOPV to bOPV, introduction of at least 1 dose of injectable, trivalent inactivated poliovirus vaccine (IPV) into childhood immunization schedules reduces risks from and facilitates responses to cVDPV2 outbreaks. (cdc.gov)
- however, careful surveillance for polioviruses and prompt, aggressive responses to polio outbreaks are still needed to realize a polio-free world. (cdc.gov)
- Only type 1 poliovirus still causes outbreaks in two countries: Pakistan and Afghanistan. (virology.ws)
- Since the 2016 removal of type 2 strains from the OPV, vaccine-derived poliovirus outbreaks have occurred in communities that are immunologically naive to poliovirus type 2 and in areas with recent use of monovalent OPV. (who.int)
- There's a bitter irony hidden at the heart of the eradication campaign: The primary tool eradicators have used to combat the virus - the oral polio vaccine created by Albert Sabin in the late 1950s - is itself causing outbreaks of the disease. (latimes.com)
- Healthcare experts say global outbreaks of vaccine-derived polio cases should prompt parents to vaccinate their children as soon as possible, and adults to ensure they're up-to-date on their polio vaccines. (yahoo.com)
- Despite this, VDPV2 outbreaks have continued-a reflection of residual vaccine virus circulating in large populations. (bmj.com)
- Here is the perspective: over the past 10 years-during which more than 10 billion doses of oral polio vaccine were given worldwide-circulating VDPV outbreaks remained rare. (bmj.com)
- The outbreaks both occurred in Ukraine, where the risk of contracting polio is particularly high since the vaccine coverage is limited . (iflscience.com)
- Today, more than five years after the global switch, the world is facing increasing outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2) in parts of Africa, Europe and the Middle East. (who.int)
- and low-quality outbreak response campaigns with monovalent type 2 Sabin OPV (mOPV2), which has been the selected vaccine for responding to these outbreaks. (who.int)
- In 2021, the Global Polio Eradication Initiative (GPEI) announced a new strategy that addresses cVDPV2 outbreaks as a goal to interrupt all poliovirus everywhere.1 Included in this strategy is the introduction of a new tool for cVDPV2 outbreak response: the novel oral polio vaccine type 2 (nOPV2). (who.int)
Sabin13
- By July of 2016 all remaining stocks of the Sabin type 2 poliovirus strains, which are used to produce OPV, will also be destroyed . (virology.ws)
- containing Sabin strain types 1 and 3) subsequent to the certified eradication of wild type poliovirus (WPV) type 2 in 2015 ( 1 - 3 ). (cdc.gov)
- In November 2020, the World Health Organization (WHO) Emergency Use Listing procedure authorized limited use of type 2 novel OPV (nOPV2), a vaccine modified to be more genetically stable than the Sabin strain, for cVDPV2 outbreak response ( 3 , 5 ). (cdc.gov)
- type 2 immunization programs in April 2016 in vaccine-derived, or Sabin) in any sample was eradicated in 1999, and type 3 was a global switch from trivalent OPV from any source is generally considered to last seen in 2012. (who.int)
- [2] [11] Another attenuated live oral polio vaccine was developed by Albert Sabin and came into commercial use in 1961. (wikipedia.org)
- In a recent study published in eClinicalMedicine, researchers assessed the immune persistence of the Sabin strain-derived inactivated poliovirus vaccine (sIPV) compared to wild poliovirus seed strains (wIPV) in children. (expresshealthcaremgmt.com)
- History of Sabin attenuated poliovirus oral live vaccine strains. (who.int)
- The ful data concerning the history of attenuated poliovirus strains developed by one of us (Sabin, 1965) for vaccine production do not appear in a single journal. (who.int)
- 3 Vaccine derived polioviruses arise when genetic reversion events in the Sabin oral polio vaccine (OPV) increase their, otherwise attenuated, transmissibility and neurovirulence. (bmj.com)
- Prior poliovirus transmission modeling of globally-coordinated type-specific cessation of oral poliovirus vaccine (OPV) assumed creation of Sabin monovalent OPV (mOPV) stockpiles for emergencies and explored the potential need to restart OPV if the world reached a specified cumulative threshold number of cases after OPV cessation. (cdc.gov)
- Oral polio vaccine developed by Albert Sabin from weakened live polio viruses and introduced in 1961. (scienceclarified.com)
- The advantage of the Sabin vaccine is that it is given orally and offers protection with only a single dose. (scienceclarified.com)
- About nOPV2 · nOPV2 is a genetically modified version of the attenuated Sabin vaccine. (who.int)
Strains4
- OPV was made by weakening the three strains of poliovirus that caused disease by growing them in monkey kidney cells. (chop.edu)
- The pneumococcal vaccine is made from the polysaccharide capsules of 23 different bacteria strains. (ihs.gov)
- Over the past few years we have had frequent requests for the details such as isolation and attenuation and accordingly we felt that bringing the data together in the report below would be both helpful and informative to those involved in the production and control of poliovirus vaccine (oral) prepared from these strains. (who.int)
- Collectively these four organisms account for a great number of cases of diarrhea across the world and vaccines targeting the most common strains of all these pathogens are currently being developed, improved and undergoing trials across the globe. (biomedcentral.com)
Live attenuated4
- This marked progress has been achieved through widespread use of oral poliovirus vaccines (OPVs), most commonly trivalent OPV (tOPV), which contains types 1, 2, and 3 live, attenuated polioviruses and has been a mainstay of efforts to prevent polio since the early 1960s. (cdc.gov)
- The first successful demonstration of a polio vaccine was by Hilary Koprowski in 1950, with a live attenuated virus which people drank. (wikipedia.org)
- [21] Three doses of live-attenuated OPV produce protective antibodies to all three poliovirus types in more than 95% of recipients. (wikipedia.org)
- Inactivated and trivalent oral poliovirus vaccines contain either formalin- inactivated or live, attenuated poliovirus, respectively, of the three serotypes. (who.int)
Serotypes8
- For the first time since April of 1955, recipients of poliovirus vaccine will no longer receive all three serotypes. (virology.ws)
- When the IPV (injection) is used, 90% or more of individuals develop protective antibodies to all three serotypes of polio virus after two doses of inactivated polio vaccine (IPV), and at least 99% are immune to polio virus following three doses. (wikipedia.org)
- Indeed, of the 3 serotypes of wild poliovirus (the causative agent of the disease), only type 1 remains in Afghanistan and Pakistan , the 2 countries where polio (i.e., wild poliovirus) is still endemic. (asm.org)
- Interference among the three attenuated poliovirus serotypes was minimized with a 'balanced- formulation' vaccine, and serologic responses after IPV were optimized by adjusting the antigenic content of each inactivated poliovirus serotype. (who.int)
- This study measured seroprevalence of antibodies against poliovirus serotypes 1 to 3 (PV1, PV2 and PV3) in 7-month-old infants who had received at least 4 doses of trivalent oral polio vaccine. (who.int)
- Using cluster sampling, 72 eligible infants were tested for antibody against the 3 poliovirus serotypes according to WHO guidelines. (who.int)
- Only 63.9% of participants were seropositive for antibodies against all 3 poliovirus serotypes. (who.int)
- Except for PV2, the seroprevalence of antibody against the other 2 poliovirus serotypes, especially PV3, was unsatisfactory. (who.int)
1950s and 1960s3
- Dr. Wright tells Good Housekeeping that U.S. doctors first began administering the earliest versions of polio vaccines in the 1950s and 1960s. (yahoo.com)
- When polio vaccines were developed in the 1950s and 1960s, they led to a dramatic decrease in the spread of poliovirus, eliminating the disease in many countries. (unfoundation.org)
- All but two countries have managed to eliminate wild poliovirus since vaccines were introduced in the 1950s and 1960s. (technologyreview.com)
Bivalent6
- The first stage of OPV withdrawal involved a global, synchronized replacement of tOPV with bivalent OPV (bOPV) containing only types 1 and 3 attenuated polioviruses, planned for April 18-May 1, 2016, thereby withdrawing OPV type 2 from all immunization activities ( 3 ). (cdc.gov)
- This past Sunday the World Health Organization orchestrated a synchronized switch from trivalent to bivalent oral poliovirus vaccine (OPV) in 150 countries. (virology.ws)
- Of course, re-introduction of this vaccine will be accompanied by more circulating vaccine-derived poliovirus in the environment, and vaccine-associated disease, the very event WHO is trying to end with the trivalent to bivalent switch. (virology.ws)
- Replacement of the trivalent oral poliovirus vaccine (tOPV) with bivalent types 1 and 3 oral poliovirus vaccine (bOPV) and global introduction of inactivated poliovirus vaccine (IPV) are major steps in the polio endgame strategy. (bvsalud.org)
- We used quantitative polymerase chain reaction analysis to measure vaccine shedding in 300 seronegative infants aged 6-11 months and in 218 children aged 1-4 years 7 days after administration of monovalent or bivalent OPV. (liverpool.ac.uk)
- Referred to as the "global switch," the withdrawal of the trivalent oral polio vaccine (tOPV) was replaced with the bivalent oral polio vaccine (bOPV). (who.int)
20165
- In 2016 WHO PQS introduced a grading scale: A, B and C. Appliances graded A are certified as low vaccine freezing risk even if baskets are not used (see paragraph on freeze-protection). (who.int)
- Nigeria is the latest country to have officially stopped endemic transmission of wild poliovirus, with its last reported case in 2016. (wikipedia.org)
- Available at http://www.who.int/biologicals/vaccines/BS2185_OPV_Post_ECBS_DB_TZ_DBFinal12Feb2013.pdf, accessed February 2016. (who.int)
- Indeed, wild poliovirus type 2 was eradicated globally in 2015, 7 and since April 2016, no OPV in use for routine immunisation around the world has contained the type 2 virus. (bmj.com)
- Following the last wild poliovirus type 2 (WPV2) case in northern India in 1999 and the global certification of the WPV2 eradication in September 2015, type 2-containing oral polio vaccines (OPV) were withdrawn from national immunization programmes worldwide in April 2016 to prevent the incidence of vaccine-derived polioviruses (VDPVs) caused by type 2 vaccine virus. (who.int)
Outbreak9
- Whether they will continue to do so long enough to cause an outbreak of paralytic disease in the cohort of new infants that do not receive type 2 vaccine is a mattern of conjecture. (virology.ws)
- In case there is an outbreak, monovalent type 2 oral poliovirus vaccine is being stockpiled by WHO. (virology.ws)
- After use of the monovalent vaccine, the emergence of vaccine-derived poliovirus unrelated to the outbreak virus was detected in healthy children and environmental samples. (who.int)
- This report describes the detection of this poliovirus in the Philippines after use of the monovalent type 2 OPV for outbreak response. (who.int)
- We describe the emergence of vaccine-derived poliovirus unrelated to the outbreak detected after supplementary immunization activities using the monovalent type 2 OPV. (who.int)
- a) Strengthen detection of any poliovirus transmission, respond quickly to a poliovirus outbreak, and improve the quality of supplemental immunization activities. (who.int)
- Stopping any polio outbreak starts with vaccine procurement, transport by airplanes and trucks, distribution involving complex logistics, and eventually the oral administration of the vaccine by drops in the mouths of every eligible child. (polioeradication.org)
- The first serious outbreak of vaccine-derived polio was in Haiti and the Dominican Republic in 2000, six years after the WHO certified the Americas polio-free. (latimes.com)
- Even as wild virus rates plunged there, an outbreak of vaccine-derived poliovirus caused about 350 paralytic cases. (latimes.com)
Transmission of poliovirus2
- The most important step in eradication of polio is interruption of endemic transmission of poliovirus. (wikipedia.org)
- While IPV does an excellent job at protecting individuals from paralytic disease, it cannot stop community transmission of poliovirus-but OPV can. (asm.org)
Called oral polio vaccine1
- A more convenient form, called oral polio vaccine (OPV), was given as liquid drops via the mouth. (chop.edu)
Immune11
- Ebola monoclonal antibodies may interfere with immune response of live vaccines. (medscape.com)
- Both biopharmaceuticals are regarded as vaccines because they elicit an immune response, either against a pathogenic microorganism or against the host's own tumour cells. (intechopen.com)
- Poliovirus that was grown in these cells was so "weakened" that, after it was swallowed, it induced an immune response but didn't cause disease. (chop.edu)
- This suggests that the immune response to OPV is on a continuum, rather than an all-or-nothing phenomenon, that depends on efficient vaccine virus replication. (liverpool.ac.uk)
- Viral interference and innate antiviral immune mechanisms might be more important determinants of the immunogenicity of live-virus oral vaccines. (ox.ac.uk)
- Extremely rarely, it can cause polio in people who receive the vaccine and also have a weak immune system. (technologyreview.com)
- The effect of elevated temperature on viral viability is clear: after one week at 37°C in a buffered solution, adenovirus vaccine vectors lose all infectivity and cannot stimulate immune responses. (virology.ws)
- Vaccines, she said, make your immune system react stronger, quicker and longer when harmful germs invade your body. (jamaica-gleaner.com)
- Some vaccines like oral poliovirus (OPV), measles, mumps, rubella (MMR) and BCG (to protect against tuberculosis) are made of live weakened forms of germs and may, in rare cases, cause this disease in persons whose immune system is very weak when they are vaccinated. (jamaica-gleaner.com)
- This results both in enhanced vaccine responses and, at times, down-regulation of other immune reactivities, such as transplant rejection and the risk of developing certain immunologic diseases, such as type I diabetes. (unu.edu)
- four injections with the killed-virus vaccine prompts the body's immune system to produce antibodies that will attack any future invading forms of the disease. (scienceclarified.com)
Antibodies to poliovirus types1
- Three months after the final dose, 96%-99%, 99%-100%, and 81%-100% of infants had antibodies to poliovirus types 1, 2, and 3, respectively, and subjects with two or more prior OPV doses were significantly less likely than those with none or one prior OPV dose to excrete virus in feces after an OPV challenge. (johnshopkins.edu)
Emergence1
- The most recently detected poliovirus genetically linked to the cVDPV1 emergence (PHL-NCR-2) § circulating during the previous reporting period was found in environmental surveillance samples (sewage) in Malaysia during March 2020 ( 3 ) ( Table ) ( Figure 1 ). (cdc.gov)
BOPV1
- global removal of all OPVs in the long Since the switch from tOPV to bOPV, the Wild poliovirus type 1 caused 100% of term. (who.int)
Paralytic polio4
- Those who are infected with poliovirus can have paralytic polio or nonparalytic polio, where a person can present with constitutional, respiratory, or gastrointestinal symptoms only. (cdc.gov)
- Very rarely, it causes something called vaccine-acquired paralytic polio. (latimes.com)
- Some children who have received 12 doses of the oral vaccine have still come down with paralytic polio, possibly because intestinal infections common in the developing world may change the intestines, leaving fewer receptors for the oral vaccine to latch on to. (latimes.com)
- Those who have received all of their childhood vaccinations, and children who are up-to-date on their routine vaccinations, don't need to worry about contracting paralytic polio - or seek a booster vaccine," says Shira Doron, M.D. , infectious disease physician and hospital epidemiologist at Tufts Medical Center . (yahoo.com)
National immunization4
- Organization of "national immunization days" to provide supplementary doses of oral polio vaccine to all children less than five years old. (wikipedia.org)
- We develop updated decision trees of national immunization options for poliovirus vaccines considering different possibilities for OPV restart. (cdc.gov)
- Thus, recent WHO policy has directed national immunization programs worldwide to transition to inactivated polio vaccine (IPV) regimens by 2015. (stanford.edu)
- fants, born from 25 April 2010 to 25 national immunization schedule, by the Sistan-va-Baluchestan province, May 2010) living in the rural areas of 6th month of age, all infants should have located in the south-east of the Islamic Chabahar (i.e. people living outside the received at least 4 doses of trivalent oral Republic of Iran, has common borders municipal territories of Chabahar). (who.int)
1960s1
- Thanks to the introduction of safe and effective vaccines in the late 1950s and early 1960s, the condition has largely been forgotten as a public health concern in most high resource settings, including in the UK. (bmj.com)
People infected with poliovirus2
- Most people infected with poliovirus have no symptoms, and many recover without complications. (medlineplus.gov)
- Most people infected with poliovirus will not experience any symptoms, and around 25% of people infected will experience flu-like symptoms. (unfoundation.org)
Endemic5
- On 25 September 2015, Nigeria, the only remaining polio-endemic country in Africa, was removed from the list of polio-endemic countries after more than a year of zero confirmed cases of wild poliovirus. (who.int)
- Travelers to areas where wild poliovirus is epidemic or endemic should have completed a primary series of poliovirus vaccine. (ihs.gov)
- Wild poliovirus has been eradicated in all continents except Asia, and as of 2020[update], Afghanistan and Pakistan are the only two countries where the disease is still classified as endemic. (wikipedia.org)
- Several key strategies have been outlined for stopping polio transmission: High infant immunization coverage with four doses of oral polio vaccine (OPV) in the first year of life in developing and endemic countries, and routine immunization with OPV or IPV elsewhere. (wikipedia.org)
- Oral Cholera Vaccines (OCV) are good candidates for the control of cholera particularly in endemic areas. (biomedcentral.com)
Form of poliovirus1
- No. The type of poliovirus detected in Jerusalem, London, and New York is a form of poliovirus called circulating vaccine-derived poliovirus, which is not the same as the wild poliovirus detected in Malawi and Mozambique. (unfoundation.org)
TOPV2
- However, although the cessation of tOPV use is a major milestone toward the completion of the global effort to eradicate polio, vigilant surveillance for all polioviruses, including type 2 polioviruses, is still needed. (cdc.gov)
- Any tOPV found in a vaccine storage refrigerator or freezer in the future should be destroyed consistent with the Global Action Plan to Minimize Poliovirus Facility-Associated Risk. (cdc.gov)
Infants8
- Infants in all groups were challenged with monovalent type 2 vaccine (mOPV2) at 18 weeks (groups 1, 3, and 4) or 40 weeks (groups 2 and 5). (bvsalud.org)
- The effect of azithromycin on the immunogenicity of oral poliovirus vaccine: a double-blind randomised placebo-controlled trial in seronegative Indian infants. (ox.ac.uk)
- METHODS: We did a double-blind, randomised, placebo-controlled trial of the effect of azithromycin on the immunogenicity of serotype-3 monovalent oral poliovirus vaccine given to healthy infants living in 14 blocks of Vellore district, India. (ox.ac.uk)
- Infants were eligible to participate if they were 6-11 months old, available for the study duration, and lacked serum neutralising antibodies to serotype-3 poliovirus. (ox.ac.uk)
- Infants were randomly assigned (1:1) at enrolment to receive oral 10 mg/kg azithromycin or placebo once daily for 3 days, followed by serotype-3 monovalent oral poliovirus vaccine on day 14. (ox.ac.uk)
- Prior to the introduction of the vaccine, it was estimated that 17% of all cases of Hib disease occurred in infants less than 6 months of age. (theodora.com)
- ABSTRACT Despite high coverage rates of polio vaccine in the Islamic Republic of Iran, the seroconversion rates of infants may be inadequate. (who.int)
- The pres- Target population country has had no report of circula- ence of such a gap will jeopardize the The target population were 7-month- tion of wild polioviruses throughout confidence of the country in its high old infants (210- to 240-day-old in- the country ( 1 ). (who.int)
19556
- Polio vaccine has been available since 1955. (chop.edu)
- The inactivated polio vaccine (IPV) was available first, given as a shot, in 1955. (chop.edu)
- Since the polio vaccine was invented in 1955, polio has been nearly stamped out in the U.S. (massgeneral.org)
- [10] The success of an inactivated (killed) polio vaccine, developed by Jonas Salk , was announced in 1955 . (wikipedia.org)
- In 1955, the vaccine was officially pronounced effective, potent, and safe in almost 90 percent of cases. (scienceclarified.com)
- The currently available vaccines are more immunogenic than the original IPV introduced in 1955. (aafp.org)
Pertussis1
- Most childhood vaccines she said are made of harmless inactivated or dead particles called antigens that cannot cause the disease they are supposed to prevent, like tetanus (lock jaw), Pertussis (whooping cough), diphtheria, Hepatitis B, inactivated poliovirus (IPV), influenza (the flu) and human papillomavirus (HPV) vaccines. (jamaica-gleaner.com)
Contains a weakened form1
- One type of vaccine, oral polio vaccine (OPV), contains a weakened form of the polio virus. (iflscience.com)
Risk of vaccine-derived polio2
- [17] IPV replaced the oral vaccine in many developed countries in the 1990s mainly due to the (small) risk of vaccine-derived polio in the oral vaccine. (wikipedia.org)
- it has largely blocked any risk of vaccine-derived polio spread domestically since. (yahoo.com)
Polio cases1
- Total polio cases (combined wild and circulating vaccine-derived) have dropped 97.5% from 35,251 (reported) in 1988 to 894 (confirmed) in 2022. (wikipedia.org)
Types of polio vaccines2
Infectious2
- Developing a great vaccine is not the only requirement for preventing infectious disease: you also have to be able to deploy it. (virology.ws)
- In the ensuing years, vaccines for more than 20 infectious diseases have been developed, and in 1977, Jenner's original experiment was brought to full fruition when smallpox was eradicated worldwide 6 . (nature.com)
Infection6
- However, polio vaccine can be given if a pregnant person is at increased risk for infection and requires immediate protection. (medlineplus.gov)
- In a sense, because the vaccine induces antibodies in the bloodstream, and not the intestines, IPV induces a "second line" of defense against infection. (chop.edu)
- However, under conditions of long-term vaccine virus circulation in under-vaccinated populations, mutations can reactivate the virus to produce a polio-inducing strain, while OPV can also, in rare circumstances, induce polio or persistent asymptomatic infection in vaccinated individuals, particularly those who are immunodeficient. (wikipedia.org)
- An explanation of how stool samples are transported over such a distance starts with why: monitoring children under 15 years of age for signs of AFP, which is the most common sign of poliovirus infection. (polioeradication.org)
- Atoltivimab, maftivimab, and odesivimab-ebgn may lower your body's resistance and there is a chance you might get the infection the vaccine is meant to prevent. (drugs.com)
- Vaccines are tools for prevention of infection illnesses, not treatment. (jamaica-gleaner.com)
Viral4
- Based on the state-of-play in Belgium, this chapter discusses examples of regulatory journeys of applications with genetically modified viral vectors and novel vaccine candidates that have been reviewed by GMO national competent authorities in Belgium and in Europe. (intechopen.com)
- C.04.130 No fabricator shall permit the introduction of any bacterial or viral cultures other than those used in the manufacture of poliovirus vaccine, live, oral on any premises that are used for the manufacture of poliovirus vaccine, live, oral. (gc.ca)
- All viral vaccines must either be stored frozen, or kept at low temperatures. (virology.ws)
- The ability to preserve viral vaccines on a small filter also allows simple administration of the vaccine. (virology.ws)
Wild polioviruses2
- However, for adults who have not had a primary series and are at greater- risk than the general population of exposure to wild polioviruses because of foreign travel or health occupation, IPV Is preferred since the risk of OPV-associated paralysis is slightly higher In adults than in children. (ihs.gov)
- Health-care personnel in close contact with patients who may be excreting wild polioviruses, and laboratory personnel handling specimens that may contain wild polioviruses, should have completed a primary series of poliovirus vaccine. (ihs.gov)
Jonas Salk3
- But after the break, Part 2 opens, where OPV has become the villain, and IPV [the inactivated vaccine Jonas Salk developed in the early 1950s], the forgotten one, becomes the real hero. (latimes.com)
- Polio vaccine developed by Jonas Salk in the mid-1950s from dead polio viruses and given through injection. (scienceclarified.com)
- In the early 1950s, American microbiologist Jonas Salk (1914-1995) developed the first vaccine to prevent the spread of the disease. (scienceclarified.com)
Detection3
- The primary outcome was detection of serum neutralising antibodies to serotype-3 poliovirus at a dilution of one in eight or more on day 35 and was assessed in the per-protocol population (ie, all those who received azithromycin or placebo, oral poliovirus vaccine, and provided a blood sample according to the study protocol). (ox.ac.uk)
- However, polio returned to the wider consciousness in the UK last week with the detection of vaccine derived poliovirus type 2 (VDPV2) in sewage samples taken in north London. (bmj.com)
- But thanks to the detection of polioviruses in sewage in North and North East London, where we live, she is one of hundreds of thousands of children between one and nine in the city who are being offered a booster dose. (technologyreview.com)
Tetanus1
- The stool IgM response to parenteral tetanus toxoid and oral poliovirus vaccine was significantly higher in the breastfed group. (unu.edu)